Compounds > isradipine
Page last updated: 2024-10-29

isradipine and Blood Pressure, High

isradipine has been researched along with Blood Pressure, High in 346 studies

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Research Excerpts

ExcerptRelevanceReference
"Compare the efficacy of isradipine to that of nicardipine for the control of arterial hypertension following coronary artery bypass graft (CABG)."9.10[Comparison of nicardipine and isradipine in hypertension following coronary artery bypass graft]. ( Achkouty, R; Antakly, MC; Haddad, F; Hayek, G; Khater-Rassi, D; Madi-Jebara, S; Yazigi, A, 2002)
"Isradipine lowered the maternal mean arterial blood pressure effectively in women with nonproteinuric hypertension but did not do so in women with proteinuria at recruitment or appearing during treatment."9.08Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. ( Andersson, KE; Forman, A; Ingemarsson, I; Lindberg, B; Lindeberg, S; Lunell, NO; Marsàl, K; Skajaa, K; Wide-Swensson, DH, 1995)
"The efficacy of isradipine, a new antihypertensive dihydropyridine calcium antagonist, was prospectively studied in Ethiopian patients with uncontrolled severe hypertension on multiple antihypertensive agents."9.08The efficacy of isradipine in uncontrolled hypertension in Ethiopian patients. ( Habte, B; Zewdu, W, 1995)
"A multicenter, randomized, double-blind trial compared the safety and efficacy of the dihydropyridine isradipine with the angiotensin-converting enzyme (ACE) inhibitor enalapril given twice daily for mild hypertension."9.08A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension. ( Eisner, GM; Jain, AK; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR, 1995)
"Antihypertensive Efficacy and Tolerability of Isradipine in Patients with Severe Hypertension/Results of an open multicenter study."9.08[Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study]. ( Burger, KJ; Dehner, R, 1996)
"Isradipine does not harm immunohematopoietic reconstitution after BMT; therefore, it may be used in this setting, although the previously reported incidence of hypertension has been exaggerated."9.08Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. ( Bursztyn, M; Nagler, A; Or, R; Zelig, O, 1997)
"Patients with nifedipine-induced gingival hyperplasia (GH) often require continued calcium channel blocker therapy."9.08Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. ( Bednarczyk, EM; Bissada, NF; Carlson, M; Sheehan, H; Westbrook, P, 1997)
" This study evaluated the renal effects, along with the efficacy, of isradipine in two subgroups of patients with mild to moderate essential hypertension (EH), defined according to plasma renin activity (PRA)."9.08Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity. ( Allikmets, K; Parik, T; Teesalu, R, 1997)
"This randomized, double-blind, placebo-controlled study was aimed at detecting cerebrovascular effects of isradipine and enalapril in patients with moderate hypertension depending on the presence and grade on unilateral stenosis of internal carotid artery (ICA)."9.08Comparison of isradipine and enalapril effects on regional carotid circulation in patients with hypertension with unilateral internal carotid artery stenosis. ( Akopov, SE; Simonian, NA, 1997)
"This study was designed to evaluate in 45 hypertensive patients with left ventricular hypertrophy (LVH) the effects of a 6-month course with one of three different antihypertensive regimens (the calcium channel blocker isradipine, the angiotensin converting enzyme inhibitor spirapril in monotherapy, or a combination of the two drugs, n = 15 per group) on blood pressure, LVH regression, and various functional correlates of LVH."9.08Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. ( Beldekos, D; Bresnahan, M; Cokkinos, DV; Foussas, S; Gavras, H; Gavras, I; Handanis, S; Haralabidis, G; Hatzissavas, J; Manolis, AJ, 1998)
"Fifty consecutive black patients with very severe hypertension (sitting diastolic blood pressure > or = 120 mm Hg and systolic > or = 210 mm Hg by the conventional cuff method) were treated in an open-label study (without a placebo or active drug control group) for 3 months with a long-acting preparation of isradipine (Dynacirc SRO), during which time serial changes in 24-h ambulatory blood pressure monitoring (ABPM), left ventricular (LV) mass index, and LV systolic function were evaluated."9.07Effect of isradipine in black patients with very severe hypertension. 24-hour ambulatory blood pressure monitoring and echocardiographic evaluation. ( Davis, J; Sareli, P; Skoularigis, J; Skudicky, D; Strugo, V; Weinberg, J; Zambakides, C, 1994)
"Antihypertensive Long-term Therapy with Isradipine/Improvement of coronary flow reserve in patients with arterial and microvascular angina In patients with arterial hypertension coronary flow reserve is often impaired due to left ventricular (LV) hypertrophy and alterations of the coronary microcirculation."9.07[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina]. ( Motz, W; Strauer, BE; Vogt, M, 1994)
"Intravenous isradipine was effective and well tolerated in patients with hypertension after CABG and offers an additional therapeutic option to treat patients after cardiac surgery."9.07Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison of intravenous isradipine and sodium nitroprusside. ( Brister, N; Cohen, M; Hines, R; Leslie, J; Levy, JH; Martin, H; Marty, A; Savino, J; Yared, JP, 1994)
" Patients with essential hypertension were treated for 8 weeks with either isradipine focus of double-blind study."9.07Treatment of hypertension with dihydropyridine calcium antagonists and aspirin. ( Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L, 1994)
"The aim of this study was to compare the tolerability and efficacy of isradipine and felodipine in the treatment of mild-moderate hypertension."9.07A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993)
"In this multicenter, placebo-controlled study, 16 patients with mild to moderate essential hypertension were treated with 10 mg/day isradipine retard (PN 200-110, Lomir SRO, CAS 75695-93-1) for 3 weeks."9.07[Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo]. ( Anlauf, M; Burger, KJ, 1993)
"5 mg of isradipine twice daily in patients with mild-to-moderate hypertension, as seen in general practice."9.07Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS). ( Magometschnigg, D, 1993)
"The objective of this study was to compare the tolerability of isradipine and felodipine in patients with mild-to-moderate hypertension."9.07A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993)
"This open-label trial of isradipine was carried out in 3422 outpatients by 893 general practitioners to assess the efficacy, safety, and tolerability of isradipine as monotherapy in mild-to-moderate hypertension."9.07Efficacy, safety, and tolerability of isradipine in hypertension as used in general practice in a developing country (Pakistan). ( Hashmi, MS; Khan, AH; Samad, A, 1993)
"This multicenter, double-blind, randomized trial of 1 year's duration compared the safety and efficacy of isradipine, methyldopa, and placebo in 368 men, aged 40 to 65 years, with mild-to-moderate essential hypertension."9.07A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group. ( Cristal, N; Yodfat, Y, 1993)
"The new slow-release oral formulation (SRO) of isradipine, a dihydropyridine calcium antagonist, was evaluated in 57 patients who had moderate-to-severe hypertension following a 2-week wash-out period and a 2-week placebo period."9.07Efficacy of slow-release oral isradipine in moderate-to-severe hypertension with add-on spirapril. ( Abarquez, RF; Castillo, RR; Sy, RG, 1993)
" Isradipine was used as first-line antihypertensive treatment in 15 patients who had mild-to-moderate hypertension and LVH, and who were studied before and after 6 months of treatment."9.07Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients. ( Antonopoulos, S; Athanasopoulos, G; Cokkinos, DV; Handanis, S; Kolovou, G; Manolis, AJ, 1993)
"The objective of this study was to analyze the long-term hemodynamic effects of the calcium antagonist isradipine in mild hypertension compared with those of the beta 1-selective adrenoceptor antagonist atenolol, focusing in particular on the development of cardiac hypertrophy."9.07Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. ( Gleerup, G; Haedersdal, C; Mehlsen, J; Winther, K, 1993)
" Patients with essential hypertension were treated for 8 weeks with either nitrendipine (10 mg once daily) or isradipine (2."9.07Treatment of hypertension with calcium antagonists and aspirin. Effects on 24-h platelet activity. ( Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Trnovec, T; Ulicna, L, 1993)
" In a 1-year study, 32 patients with essential hypertension were randomized to treatment with either the converting enzyme inhibitor lisinopril or the calcium antagonist isradipine; hydrochlorothiazide could be added."9.07Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. ( Amery, AK; Bielen, EC; Fagard, RH; Lijnen, PJ; Tjandra-Maga, TB; Verbesselt, R, 1992)
"MIS is a one-year Multicentre Isradipine Study of the treatment of essential hypertension, in which participated seven centres in Czechoslovakia."9.07[Multicenter study of isradipine in the treatment of hypertension]. ( Balazovjech, I; Dzúrik, R; Fet'kovská, N; Kvasnicka, J; Lupínek, Z; Mayer, O; Pidrman, V; Widimský, J, 1992)
"The tolerability of isradipine was evaluated in an open trial of patients with mild-to-moderate essential hypertension as treated in general practice."9.07Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance study. ( Bara, L; Bogaert, M; De Keyser, P; Degaute, JP; Hermans, L; Lanssiers, P; Rorive, G; Six, R; Westelinck, KJ, 1992)
"At the end of a short-term (3-month) study of antihypertensive treatment of mild-to-moderate hypertension, 141 of the 200 study patients continued into a 2-year follow-up of isradipine as monotherapy or in combination with other antihypertensive agents."9.07Long-term (2-year) isradipine data in the treatment of mild-to-moderate hypertension. ( Clement, DL; D'Hont, G; De Keyser, P; Hermans, L; Meurant, JP; Rorive, G; Westelinck, KJ, 1992)
"A short-term trial of isradipine was conducted to assess its effectiveness and tolerability in the treatment of mild-to-moderate hypertension."9.07Isradipine in the treatment of mild-to-moderate hypertension in Portugal. ( Correa-Nunes, A; Mariano-Pego, G; Pereira-Miguel, JM; Rocha-Gonçalves, F, 1992)
"The clinical efficacy and tolerability of isradipine was evaluated in 63 patients with mild-to-moderate hypertension [supine systolic blood pressure (SBP) greater than or equal to 160 mm Hg and diastolic blood pressure (DBP) greater than or equal to 95 mm Hg]."9.07Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients. ( Armaganijan, D; Batlouni, M; Ghorayeb, N; Magliano, MF, 1992)
"The safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and normal or slightly impaired renal function."9.07Effects of isradipine on hypertension and renal hemodynamics. ( Dardamanis, M; Elisaf, M; Pappas, M; Sferopoulos, G; Siamopoulos, KC, 1992)
"Fourteen women with hypertension of pregnancy and who were in their last trimester were subjected to three standardized physical stress tests before and after 1-2 weeks of treatment with 5 mg of isradipine twice daily."9.07Effect of isradipine on responses to standardized physical stress tests in hypertension of pregnancy. ( Grunewald, C; Lunell, NO; Nisell, H, 1992)
"In a randomized trial, a calcium antagonist, isradipine (ISR) and sodium nitroprusside (SNP) were compared in the management of hypertension in the early period following coronary artery bypass grafting (CABG)."9.07Isradipine for the treatment of hypertension following coronary artery bypass graft surgery: a randomized trial versus sodium nitroprusside. ( David, D; Loria, Y; Ruegg, PC, 1992)
"In this study of the efficacy and safety of isradipine as first-line therapy in hypertension, 1,647 patients enrolled; 1,472 completed the 4-week placebo run-in period and began treatment with isradipine at 2."9.07Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society. ( Lüscher, TF; Waeber, B, 1991)
"The antihypertensive effects of isradipine and captopril were studied in 231 patients with mild-to-moderate hypertension in a double-blind, randomized, between-patient trial."9.07Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension. ( Fitscha, P; Hitzenberger, G; Meisner, W, 1991)
"The efficacy and safety of isradipine and nifedipine retard were compared in 51 patients with mild-to-moderate essential hypertension."9.07First clinical experience with isradipine in the treatment of hypertension in Portugal. ( Botelho, MA; Correia, JM; Mariano-Pego, G; Rocha-Gonçalves, F; Viegas, J, 1991)
"The antihypertensive effect of isradipine compared with placebo was assessed in 28 male patients (aged 40-64 years) with mild-to-moderate essential hypertension."9.07The antihypertensive action of isradipine in mild essential hypertension. ( Farragi, D; Laszt, A; Viskoper, JR, 1991)
"This was a double-blind multicenter study to compare the efficacy, tolerability and effects on the quality of life with isradipine and atenolol in the treatment of essential hypertension."9.07Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group. ( Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Kullman, S; Scherstén, B; Sivertsson, R; Sörensen, S, 1991)
"This multicenter trial compared the efficacy and safety of isradipine and enalapril in 160 patients with essential hypertension."9.07A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension. ( Eisner, GM; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR; Vargas, R; Zemel, M, 1991)
"The hypotensive effect of isradipine was assessed in 26 male patients, aged 40 to 64 years, with hypertension."9.07Twenty-four-hour blood pressure control with isradipine in mild essential hypertension. ( Faraggi, D; Laszt, A; Viskoper, JR, 1991)
"In one study of 10 patients with mild-to-moderate hypertension, equivalent total daily doses (13 +/- 2 mg) of isradipine given twice daily and a modified-release formulation of isradipine (isradipine MR) given once daily were found to control adequately 24 h ambulatory blood pressure compared with placebo (P less than ."9.07Low-dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension. ( Beekman, J; de Bruijn, JH; Diemont, WL; Hagels, G; Siegers, AM; Stegeman, CJ, 1991)
"This was a study of the effectiveness of isradipine, a calcium antagonist of the dihydropyridine group, in reversing left ventricular hypertrophy (LVH) in patients with mild-to-moderate hypertension."9.07Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine. ( Abreu, P; Ajzen, H; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Vanneta, A, 1991)
"9 years) who had developed hypertension (blood pressure greater than 140/90 mm Hg) took part in an open pilot study with the new calcium antagonist isradipine."9.07Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy. ( Feiks, A; Grünberger, W; Meisner, W, 1991)
"Hemodynamic Effects of Isradipine and Nifedipine in Hypertension Myocardial wall tension is an important determinant of the oxygen demand, the function and the degree of hypertrophy of the left ventricle."9.07[The hemodynamic effects of isradipine and nifedipine in hypertension]. ( Burger, KJ; Distler, GA; Gross, P; Koppenhagen, K; Welzel, D; Wudel, E, 1991)
"The objectives of this study were (a) to evaluate the dose-response effect of isradipine, a dihydropyridine calcium antagonist, on the heart rate and blood pressure of males with mild to moderate hypertension; and (b) to compare these results with those obtained with propranolol, a beta-adrenoceptor blocker, on a matched patient population."9.06Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol. ( Cantor, A; Cristal, N, 1990)
"Isradipine, a new calcium antagonist, was administered to 51 Pakistani patients with hypertension (36 women, 15 men; mean age 47 years) over an 8-week period."9.06Isradipine in Asian patients with hypertension. ( Hussain, S; Karim, S; Zubair, M, 1990)
"The effective and well tolerated dose of isradipine was determined in 130 Filipino patients with mild to moderate essential hypertension in a multicentre study with a 2-week placebo pretreatment period followed by an 8-week active treatment period."9.06Isradipine dose-confirmation study in Filipino patients with mild to moderate hypertension. ( Abarquez, RF; Anastacio, RV; Cabral, EI; Calleja, HB; Castillo, RR; Divinagracia, RA; Namin, EP; Porciuncula, CI, 1990)
"The calcium antagonists of the dihydropyridine group, isradipine and nifedipine, were compared in 64 patients with mild to moderate hypertension (diastolic blood pressure 95 to 110mm Hg)."9.06The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine. ( Burger, KJ; Welzel, D, 1990)
"In this double-blind cross-over study 16 patients with mild-to-moderate hypertension were treated with placebo and the dihydropyridine derivative, isradipine 5-10 mg twice daily."9.06Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension. ( Amery, A; Devos, P; Fagard, R; Hespel, P; Lijnen, P; Staessen, J; Tan, WP, 1989)
"The long-term effects (9 weeks) on renal hemodynamics of the new calcium entry blocker isradipine (PN 200-110) were assessed in 20 middle-aged male patients with essential hypertension."9.06Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension. ( Andersson, OK; Persson, B; Wysocki, M, 1989)
"One hundred eighteen patients, aged between 65 and 87 years with mild-to-moderate hypertension were given placebo or isradipine (1."9.06Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group. ( , 1989)
"A total of 152 patients with essential hypertension (World Health Organization classification I/II) entered a multicenter randomized study to assess the safety and efficacy of isradipine compared with, and in combination with, the beta-blocker atenolol."9.06A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group. ( , 1989)
"Twenty-three men with essential hypertension participated in a double-blind placebo-controlled study with a crossover design to evaluate the long-term (nine weeks) effects of isradipine on central and renal hemodynamics."9.06Renal and hemodynamic effects of isradipine in essential hypertension. ( Andersson, OK; Aurell, M; Hedner, T; Persson, B; Wysocki, M, 1989)
"One hundred seventy-eight patients, aged 30 to 85, with mild-to-moderate hypertension entered a multicenter double-blind, randomized, between-patient comparison of isradipine (0."9.06Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group. ( , 1989)
"Six hundred outpatients aged between 22 and 84 years with essential hypertension (diastolic blood pressure of at least 95 mm Hg) entered a multinational, multicenter, single-blind trial with dose titration to assess the safety, tolerability, and efficacy of isradipine in doses of 1."9.06A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension. ( Keller, A; Rüegg, PC; Sundstedt, CD; Waite, R, 1989)
"The safety and antihypertensive efficacy of PN 200-110 (isradipine), a novel calcium antagonist, are discussed in a preliminary report of double-blind, multicenter, controlled, phase III clinical trials for essential hypertension."9.06Treatment of essential hypertension with PN 200-110 (isradipine). ( Hamilton, BP, 1987)
"The effects of 10 weeks of treatment with isradipine (ISRP), a new dihydropyridine Ca antagonist, was evaluated in a prospective, randomized, double-blind, parallel group, hydrochlorothiazide (HCTZ) controlled study in patients with mild to moderate hypertension."9.06Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study. ( Gonasun, LM; Goodman, RP; Kirkendal, WM; Kontos, HA; Mohanty, PK; Samuel, P; Wright, JT, 1988)
"Isradipine is a dihydropyridine calcium antagonist used for the treatment of hypertension."8.78Cardiac effects of isradipine in patients with hypertension. ( Lund-Johansen, P, 1993)
" A MEDLINE search was conducted using the following indexing terms: isradipine, calcium-channel blockers, hypertension, and angina pectoris."8.78Isradipine--another calcium-channel blocker for the treatment of hypertension and angina. ( Lopez, LM; Santiago, TM, 1992)
"Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race."8.78Isradipine: overall clinical experience in hypertension in the United States. ( Miller, H, 1990)
"Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race."8.78Isradipine: overall clinical experience in hypertension in the United States. ( Miller, H, 1991)
"The objective of the present paper is to formulate nanostructured lipid carriers (NLCs) of a calcium channel blocker, isradipine, to enhance its oral bioavailability and prolong its antihypertensive effect apart from evaluating efficacy of the formulation in isoproterenol induced myocardial infarction in rats."8.12Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction. ( Alam, T; Ali, J; Ansari, MA; Baboota, S, 2022)
"5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome."7.73Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. ( Sirotiaková, J; Widimský, J, 2006)
"Isradipine is an effective, orally administered agent for control of hypertension in children."7.70Initial experience with isradipine for the treatment of hypertension in children. ( Groshong, T; Strauser, LM; Tobias, JD, 2000)
"To determine the appropriate dosage regimen of isradipine in black patients with severe hypertension of pregnancy, 10 patients (gestational age, 30 to 38 weeks; diastolic blood pressure [DBP], 110 to 148 mm Hg; no hypertensive crises; and normal central venous pressure) were given an isradipine infusion while the fetal heart rate was continuously recorded using a cardiotocograph."7.69Intravenous isradipine in the management of severe hypertension in pregnant and nonpregnant patients. A pilot study. ( Khedun, SM; Madhanpall, N; Maharaj, B; Moodley, J; van der Byl, K, 1994)
" We attempted to verify the effectiveness of a new calcium antagonist, isradipine 5 mg SRO, on the reversal of left ventricular hypertrophy."7.69Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy. ( Baraldi, P; Masciocco, G; Mattioli, G; Modena, MG; Rossi, R, 1994)
"The purpose of this study was to ascertain if Isradipine treatment in spontaneously hypertensive rats (SHR) decreased hypertension-dependent left ventricular and coronary vascular hypertrophy."7.69Influence of isradipine treatment on left ventricular and coronary vascular hypertrophy in spontaneously hypertensive rats. ( Amenta, F; Ferrante, F, 1994)
"The aim of our study was to investigate the effects of exercise on albuminuria and blood pressure in patients with essential hypertension, and the short-term effect of the calcium channel blocker isradipine on exercise-induced albuminuria (UAE) and blood pressure in the same patients."7.68Isradipine decreases exercise-induced albuminuria in patients with essential hypertension. ( Bossoni, S; Giustina, A; Macca, C; Romanelli, G, 1993)
"The effects of isradipine on ambulatory blood pressure, platelet aggregation, and oxygen free radicals were assessed in 30 patients with hypertension in a non-comparative 16-week study."7.68Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension. ( Chou, TC; Ding, YA; Han, CL; Lai, WY; Shiao, MF, 1992)
"To evaluate the efficacy and duration of action of iv isradipine in the control of postoperative hypertension immediately after myocardial revascularization."7.68Isradipine for treatment of acute hypertension after myocardial revascularization. ( Alpern, J; Barnette, RE; Brister, NW; McClurken, JB; Schartel, SA, 1991)
"The immediate and short-term cardiovascular effects of oral isradipine therapy were evaluated in 11 patients with mild to moderate systemic hypertension."7.68Cardiovascular effects of isradipine in essential hypertension. ( Garavaglia, GE; Grossman, E; Messerli, FH; Nunez, B; Oren, S, 1991)
"In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler echocardiographic data to investigate the antihypertensive and hemodynamic effects of isradipine 5 mg in the new slow-release oral (SRO) formulation administered once daily for 12 weeks to 10 patients with mild to moderate hypertension."7.68Slow-release isradipine in mild to moderate hypertension: hemodynamic and antihypertensive effects. ( Celentano, A; de Divitiis, O; de Simone, G; Galderisi, M; Garofalo, M; Mureddu, GF; Tammaro, P, 1991)
"In view of the possibility that cardiac hypertrophy may be reversed by isradipine, we studied the effect of two different doses of isradipine (1."7.67Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine. ( Amorim, MP; Cezaretti, ML; de Almeida, JB; Portela, J; Ramos, OL; Saragoça, MA, 1989)
"Mean isradipine dose was 0."6.70Isradipine treatment of hypertension in children: a single-center experience. ( Flynn, JT; Warnick, SJ, 2002)
" Similar results were obtained when spirapril was combined with 5 mg isradipine in the initial and final single dose, or in the 3 months' treatment (5 mg o."6.69Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. ( Boner, G; Erman, A; Rosenfeld, J; Shohat, J; Wittenberg, C, 1999)
" Twice daily dosing of isradipine was associated with partial and significant restoration of the nocturnal decrease in blood pressure (systolic blood pressure decreased 5."6.69Hypertension after liver transplantation: a predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations. ( Canzanello, VJ; Krom, RA; Porayko, MK; Schwartz, L; Taler, SJ; Textor, SC; Wiesner, RH, 2000)
"Left ventricular hypertrophy is a common clinical feature in hypertensive patients and may be associated with structural changes in vessel morphology."6.68Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. ( Heagerty, AM; Kenedi, P; Rietbrock, N; Stephens, N; Thürmann, PA; Weidinger, G, 1996)
" In patients whose blood pressure was not normalized (defined as DBP< or =90 mmHg) after 6 weeks of treatment, the dosage of either medication was doubled or, in the placebo group, was switched to the fixed combination."6.68Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. ( Antlsperger, A; Pittrow, DB; Schardt, W; Wambach, G; Weidinger, G; Welzel, D, 1997)
" Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs."6.67At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. ( De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994)
" The dosage was titrated if necessary after 4 weeks of treatment."6.67Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension. ( Chan, TY; Critchley, JA; Or, KK; Sanderson, JE; Tomlinson, B; Woo, J, 1994)
" In conclusion, treatment with dihydropyridines alone or in combination with low-dose aspirin can prevent circadian increases in platelet activity in patients with essential hypertension."6.67Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. ( Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L, 1994)
" The mean dosage was 1."6.67Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients. ( Correa-Nunes, A; Mariano-Pego, G; Moura, B; Pereira-Miguel, JM; Rocha-Gonçalves, F, 1994)
"SRO, given by oral route, in the dosage of 5 mg O."6.67[A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension]. ( Amodeo, C; Chaves, H; Francischetti, E; Jardim, PC; Lima Júnior, E; Magliano, MF; Mion Júnior, D; Nobre, F; Ribeiro, JM; Spritzer, N, 1993)
"On isradipine treatment these parameters remained unchanged."6.67A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. ( Christensen, P; Feldt-Rasmussen, B; Jensen, T; Nørgaard, K, 1993)
"Hypertension was treated with oral labetolol in combination with guanfacine if necessary."6.67Effect of isradipine on cyclosporin A-related hypertension. ( Ijzermans, JN; Schalekamp, MA; van den Dorpel, MA; Weimar, W; Zietse, R, 1994)
" The results of this study indicated that monotherapy with isradipine SRO at the recommended initial dosage of 5 mg once daily is appropriate in black patients with hypertension."6.67A comparative study of isradipine SRO and enalapril in black patients with mild-to-moderate hypertension. ( Maharaj, B; van der Byl, K, 1993)
" Both agents were able to achieve reductions in MAP to 80-90 mmHg quickly and safely, although the effects of isradipine at the dosage used were apparent sooner and gave smoother control than with sodium nitroprusside."6.67Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery. ( Chan, E; De Lange, S; Lawrence, CJ; Lestrade, A, 1993)
" No adverse reactions were reported by 68 percent of the patients in Group I and 65% of those in Group D."6.67A comparison of the safety of therapeutically equivalent doses of isradipine and diltiazem for treatment of essential hypertension. ( Abrams, AP; Black, HR; Hamilton, BP; Hamilton, JH; Isaacsohn, JL; Kochar, MS; Lewin, AJ; MacCarthy, EP; Madias, NE; Stein, GH, 1992)
"The antihypertensive efficacy and tolerability of the new calcium antagonist isradipine was assessed in 86 hypertensive patients who had pretreatment diastolic blood pressures (DBP) greater than or equal to 105 mm Hg and who were randomly allocated to a double-blind comparison of three different dosage regimens: 1."6.67Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. ( Burger, KJ; Kirch, W; Weidinger, G; Welzel, D, 1990)
"Aldosterone levels were also increased after three months, but without a subsequent decrease."6.67Isradipine in the treatment of hypertension. Some additional effects observed during a one-year study. ( Mayer, O; Polivkova, H; Rottenborn, J, 1991)
" The Montevideo Mathematical Model was used to determine the time course of the response to treatment in each dosage group."6.67Time course of the blood pressure response to oral isradipine in uncomplicated mild-to-moderate essential hypertension. ( Leary, WP; Maharaj, B; Reyes, AJ; van der Byl, K, 1991)
"It is concluded that treatment of hypertension with a compound that lowers blood pressure and inhibits platelet activation may be of clinical benefit when routinely applied in hypertensive patients."6.67Effects of isradipine on platelet function in hypertension at rest and during exercise. ( Fitscha, P; Rauscha, F; Sinzinger, H; Virgolini, I, 1991)
" The mean dosage in the isradipine group was 7."6.67Effect of isradipine and atenolol on lung function in patients with mild essential hypertension. ( Meisner, W; Reiterer, W, 1991)
"Isradipine was also well tolerated."6.67Management of perioperative hypertension using intravenous isradipine. ( Karmann, U; Keller, H; Rüegg, PC, 1991)
"Arterial hypertension is common after coronary artery-bypass grafting (CABG) surgery and may lead to postoperative complications."6.67Isradipine, a calcium antagonist, in the control of hypertension following coronary artery-bypass surgery. ( de Lange, S; Lawrence, CJ; Lestrade, A, 1991)
"The efficacy and safety of once-daily dosing of isradipine, a new calcium antagonist vasodilator, was evaluated in a multicenter, placebo-controlled trial in hypertensive patients who had supine diastolic blood pressure (SDBP) 100-119 mm Hg."6.67Placebo-controlled trial of once-a-day isradipine monotherapy in mild to moderately severe hypertension. ( Canosa, FL; Carr, AA; Cohen, M; Kirkendall, WM; Lewin, AJ; McMahon, FG; Winer, N, 1990)
"Isradipine is a new calcium antagonist of the dihydropyridine type, with marked vasodilator activity and minimum negative inotropic effects."6.67Multicentre isradipine dose-confirmation study in Thai patients with hypertension. ( Charoenlarp, K; Jaroonvesama, N; Koanantakul, B; Nontakanun, S; Tanomsup, S; Tantbirojn, P, 1990)
"Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis."6.66Efficacy and safety of isradipine in hypertension. ( Brockway, B; Carr, AA; Davidov, M; Gonasun, L; Hamilton, B; Hamilton, J; Prisant, LM; Schnaper, H; Shepherd, AM; Velasquez, M, 1989)
"Isradipine is a more specific treatment for post-aortocoronary bypass graft hypertension than nitroprusside because its systemic arterial dilating effect is associated with a minimum of other circulatory changes."6.66Use of isradipine in hypertension following coronary artery bypass surgery. ( Davies, SW; Feneck, RO; Lunnon, MW; Underwood, SM; Walesby, RK, 1989)
"Based on pooled data from three randomized placebo-controlled dose-finding studies in a total of 489 patients, the dose-response relationship for efficacy and adverse events was estimated, using the Michaelis-Menten equation: Effect = maximal effect multiplied by dose/constant plus dose."6.66Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. ( Simonsen, K; Sundstedt, CD, 1989)
"The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed."6.38Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993)
"Isradipine is a new dihydropyridine-derived calcium antagonist."6.38Isradipine: a profile in essential hypertension. ( Hansson, L, 1993)
"Isradipine is a new dihydropyridine calcium antagonist with a high degree of selectivity for the coronary, cerebral, and skeletal muscle vasculature."6.38The place of isradipine in the treatment of hypertension. ( Man in't Veld, AJ, 1991)
"Isradipine is a calcium antagonist with marked vascular selectivity and, in practical terms, is devoid of cardiac effects."6.38Isradipine in hypertension. ( Hansson, L, 1990)
" The blood pressure-lowering effect of isradipine as monotherapy is dose dependent and has shown a greater efficacy than propranolol, hydrochlorothiazide, and prazosin, without an increase in adverse effects."6.38Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension. ( Dahlöf, B, 1989)
" This pilot study was conducted to determine the appropriate dosage regimen for isradipine in black patients with severe hypertensive disorders of pregnancy."5.29Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study. ( Khedun, SM; Madhanpall, N; Maharaj, B; Moodley, J; van der Byl, K, 1994)
" Dosage was increased from 2."5.28Isradipine treatment for hypertension in general practice in Hong Kong. ( Critchley, JA; Teoh, R; Tomlinson, B; Woo, J, 1992)
"Isradipine treatment normalized blood pressure values in SHR and significantly reduced the area occupied by the medial layer and the wall-to-lumen ratio in small and medium-sized, but not in large-sized, coronary artery branches."5.28Effect of long-term isradipine treatment on the hypertension-dependent changes in coronary arteries in spontaneously hypertensive rats. ( Amenta, F; Ferrante, F, 1991)
"An open-label drug substitution study showed that controlled-release isradipine (Dynacirc-CR) can be safely substituted for amlodipine on a mg-for-mg basis in patients with mild-to-moderate hypertension."5.11Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. ( Ganz, M; Mokabberi, R; Sica, DA, 2005)
"Massive hypertensive crises relating to cerebrovascular accidents such as strokes or ruptured aneurysms, or cardiovascular dysfunction and toxicity, are an important cause of morbidity and mortality associated with cocaine or methamphetamine use."5.11Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies. ( Ait-Daoud, N; Johnson, BA; Roache, JD; Wallace, C; Wang, Y; Wells, LT, 2005)
"Compare the efficacy of isradipine to that of nicardipine for the control of arterial hypertension following coronary artery bypass graft (CABG)."5.10[Comparison of nicardipine and isradipine in hypertension following coronary artery bypass graft]. ( Achkouty, R; Antakly, MC; Haddad, F; Hayek, G; Khater-Rassi, D; Madi-Jebara, S; Yazigi, A, 2002)
"The short-term treatment with atenolol in patients with arterial hypertension and sleep apnea syndrome is associated with normalization of autonomic nervous control judged by heart rate and blood pressure variability."5.09The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. ( Kantola, I; Pelttari, L; Salo, TM; Viikari, JS; Voipio-Pulkki, LM, 1999)
"We compared the efficacy and tolerability of isradipine (ISR) and fosinopril (FOS) once-a-day administration in 17 outpatients, 9 men and 8 women, aged 35-65 years (mean +/- SD = 58 +/- 10 years), affected by mild to moderate primary systemic hypertension."5.08Evaluation of antihypertensive effects of once-a-day isradipine and fosinopril: a double-blind crossover study by means of ambulatory blood pressure monitoring. ( Cloro, C; Maio, R; Marcantonio, AM; Mattioli, PL; Perticone, F; Pugliese, F, 1995)
"Isradipine lowered the maternal mean arterial blood pressure effectively in women with nonproteinuric hypertension but did not do so in women with proteinuria at recruitment or appearing during treatment."5.08Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. ( Andersson, KE; Forman, A; Ingemarsson, I; Lindberg, B; Lindeberg, S; Lunell, NO; Marsàl, K; Skajaa, K; Wide-Swensson, DH, 1995)
"The efficacy of isradipine, a new antihypertensive dihydropyridine calcium antagonist, was prospectively studied in Ethiopian patients with uncontrolled severe hypertension on multiple antihypertensive agents."5.08The efficacy of isradipine in uncontrolled hypertension in Ethiopian patients. ( Habte, B; Zewdu, W, 1995)
"The safety and efficacy, as measured by peak/trough blood pressure reduction, of a new, once-daily, controlled-release formulation of isradipine (isradipine-CR, ICR) were evaluated in patients with mild to moderate essential hypertension during a nine-week trial."5.08Sustained blood pressure control with controlled-release isradipine (isradipine-CR). ( Chrysant, SG; Cohen, M, 1995)
"A multicenter, randomized, double-blind trial compared the safety and efficacy of the dihydropyridine isradipine with the angiotensin-converting enzyme (ACE) inhibitor enalapril given twice daily for mild hypertension."5.08A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension. ( Eisner, GM; Jain, AK; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR, 1995)
"The effects of isradipine and atenolol on platelet function and fibrinolytic activity were studied in 10 male patients with mild untreated hypertension."5.08Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? ( Gleerup, G; Mehlsen, J; Winther, K, 1995)
"The efficacy and safety of different doses of a new controlled release formulation of isradipine (isradipine-CR, ICR) were evaluated in patients with mild to moderate (stages 1 and 2) essential hypertension in a placebo-controlled study."5.08Sustained blood pressure control with controlled-release isradipine. ( Chrysant, SG; Cohen, M, 1995)
" In a prospective randomized study, 14 patients with NIDDM, hypertension, proteinuria, and renal insufficiency were given either isradipine (n = 7) or nifedipine XL (n = 7) for 6 months."5.08Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. ( Abbott, K; Bakris, GL; Smith, A, 1996)
"Antihypertensive Efficacy and Tolerability of Isradipine in Patients with Severe Hypertension/Results of an open multicenter study."5.08[Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study]. ( Burger, KJ; Dehner, R, 1996)
"Isradipine does not harm immunohematopoietic reconstitution after BMT; therefore, it may be used in this setting, although the previously reported incidence of hypertension has been exaggerated."5.08Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. ( Bursztyn, M; Nagler, A; Or, R; Zelig, O, 1997)
"To evaluate the dosage and effectiveness of isradipine to control acute or chronic hypertension in pediatric patients."5.08Isradipine therapy in hypertensive pediatric patients. ( Jacobson, PA; Johnson, CE; Song, MH, 1997)
"Patients with nifedipine-induced gingival hyperplasia (GH) often require continued calcium channel blocker therapy."5.08Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. ( Bednarczyk, EM; Bissada, NF; Carlson, M; Sheehan, H; Westbrook, P, 1997)
" This study evaluated the renal effects, along with the efficacy, of isradipine in two subgroups of patients with mild to moderate essential hypertension (EH), defined according to plasma renin activity (PRA)."5.08Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity. ( Allikmets, K; Parik, T; Teesalu, R, 1997)
"Patients with mild to moderate diastolic hypertension and LV mass in excess of 1 SD of normal values were randomized to isradipine (n = 89) or hydrochlorothiazide therapy (n = 45)."5.08Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. ( Chase, GA; Cushman, WG; Gottdiener, JS; Gottdiener, PS; Narayan, P; Papademetriou, V; Zachariah, PK, 1997)
"This randomized, double-blind, placebo-controlled study was aimed at detecting cerebrovascular effects of isradipine and enalapril in patients with moderate hypertension depending on the presence and grade on unilateral stenosis of internal carotid artery (ICA)."5.08Comparison of isradipine and enalapril effects on regional carotid circulation in patients with hypertension with unilateral internal carotid artery stenosis. ( Akopov, SE; Simonian, NA, 1997)
" We identified 43 subjects from general practice with uncomplicated mild to moderate hypertension to compare the effects of the calcium antagonist isradipine with that of the beta-blocker atenolol on platelet function, plasma beta-thromboglobulin levels, fibrinolysis, and serum lipids in a randomised double-blind parallel group study."5.08Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects. ( Carney, S; Gillies, A; Mason, A; McPherson, J; Smith, A; Taylor, M, 1997)
"The effects of two antihypertensive regimens (isradipine and hydrochlorothiazide-amiloride) on the ratio between media thickness and lumen diameter of subcutaneous arteries and on left ventricular mass in essential hypertension were compared."5.08Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. ( Aalkjaer, C; Lederballe, O; Mulvany, MJ; Schroeder, AP; Sihm, I; Thygesen, K, 1998)
"5 mg; diuretic, hydrochlorothiazide [HCTZ] 25 mg; and angiotension converting enzyme-inhibitor, spirapril 6 mg) on obese patients with sleep disordered breathing and hypertension were compared by the ambulatory blood pressure measurement (ABPM)."5.08Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. ( Hietanen, EK; Kantola, IM; Kataja, MJ; Pelttari, LH; Salo, TT, 1998)
"This study was designed to evaluate in 45 hypertensive patients with left ventricular hypertrophy (LVH) the effects of a 6-month course with one of three different antihypertensive regimens (the calcium channel blocker isradipine, the angiotensin converting enzyme inhibitor spirapril in monotherapy, or a combination of the two drugs, n = 15 per group) on blood pressure, LVH regression, and various functional correlates of LVH."5.08Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. ( Beldekos, D; Bresnahan, M; Cokkinos, DV; Foussas, S; Gavras, H; Gavras, I; Handanis, S; Haralabidis, G; Hatzissavas, J; Manolis, AJ, 1998)
"5 mg isradipine on the low density lipoproteins (LDL) entry into the carotid and femoral arteries of 12 hypertensive patients with primary hyperlipoproteinemia (total cholesterol >6."5.08Isradipine lowers human arterial low density lipoprotein retention in vivo. ( Fitscha, P; Kritz, H; O'Grady, J; Sinzinger, H, 1998)
"Twelve patients with essential hypertension were randomized in a double-blind cross-over study to investigate the blood pressure BP-lowering activity of isradipine regular formulation (RF) 2."5.07Does isradipine modified release 5 mg once daily reduce blood pressure for 24 hours? ( Amery, A; Celis, H; Fagard, R; Staessen, J; Thijs, L, 1993)
"Fifty consecutive black patients with very severe hypertension (sitting diastolic blood pressure > or = 120 mm Hg and systolic > or = 210 mm Hg by the conventional cuff method) were treated in an open-label study (without a placebo or active drug control group) for 3 months with a long-acting preparation of isradipine (Dynacirc SRO), during which time serial changes in 24-h ambulatory blood pressure monitoring (ABPM), left ventricular (LV) mass index, and LV systolic function were evaluated."5.07Effect of isradipine in black patients with very severe hypertension. 24-hour ambulatory blood pressure monitoring and echocardiographic evaluation. ( Davis, J; Sareli, P; Skoularigis, J; Skudicky, D; Strugo, V; Weinberg, J; Zambakides, C, 1994)
"Antihypertensive Long-term Therapy with Isradipine/Improvement of coronary flow reserve in patients with arterial and microvascular angina In patients with arterial hypertension coronary flow reserve is often impaired due to left ventricular (LV) hypertrophy and alterations of the coronary microcirculation."5.07[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina]. ( Motz, W; Strauer, BE; Vogt, M, 1994)
"This is the first report of long-term use (one year) of isradipine, a new dihydropyridine calcium channel blocker, in the treatment of elderly patients with essential hypertension."5.07One year experience of elderly hypertensive patients with isradipine therapy. ( Abrams, A; Culter, R; Hamilton, BP; Hamilton, JH; Holtzman, JL; Kirkendall, WM; Matthews, K; Neri, G; Stein, GH, 1994)
"The aim of the present study was to evaluate the effect of dihydropyridine calcium antagonist isradipine on left ventricular (LV) structure and function in patients with essential hypertension."5.07Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril. ( Celentano, A; de Divitiis, O; Galderisi, M; Garofalo, M; Oliviero, M; Petrocelli, A; Tammaro, P, 1994)
"Intravenous isradipine was effective and well tolerated in patients with hypertension after CABG and offers an additional therapeutic option to treat patients after cardiac surgery."5.07Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison of intravenous isradipine and sodium nitroprusside. ( Brister, N; Cohen, M; Hines, R; Leslie, J; Levy, JH; Martin, H; Marty, A; Savino, J; Yared, JP, 1994)
"The effects of isradipine (Lomir, CAS 75695-93-1) and metoprolol (CAS 37350-58-6) on geometry and arterial compliance of the arteria brachialis of 14 patients each with essential hypertension were compared acutely and after three months of therapy by means of pulsed Doppler sonography and the determination of pulse wave velocity."5.07[Vasoselective, substance-specific actions of isradipine on the great arteries of hypertensives in comparison to metoprolol]. ( Bräutigam, M; Burger, KJ; Del Pino, M; Levenson, J; Merli, I; Simon, A; Welzel, D, 1994)
" Patients with essential hypertension were treated for 8 weeks with either isradipine focus of double-blind study."5.07Treatment of hypertension with dihydropyridine calcium antagonists and aspirin. ( Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L, 1994)
"The aim of this study was to compare the tolerability and efficacy of isradipine and felodipine in the treatment of mild-moderate hypertension."5.07A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993)
"In this multicenter, placebo-controlled study, 16 patients with mild to moderate essential hypertension were treated with 10 mg/day isradipine retard (PN 200-110, Lomir SRO, CAS 75695-93-1) for 3 weeks."5.07[Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo]. ( Anlauf, M; Burger, KJ, 1993)
"Antihypertensive efficacy and tolerability of a 4-week treatment each with the modified release formulation of the calcium antagonist isradipine (5 mg; Lomir SRO, CAS 75695-93-1) were compared with those of nitrendipine (20 mg) (both with morning intake) in 51 patients with mild to moderate hypertension using a double-blind, intraindividual crossover study."5.07[Circadian antihypertensive action and tolerability of a sustained-release form of isradipine in an intra-individual comparison with nitrendipine]. ( Burger, KJ; Lohmann, FW; Welzel, D, 1993)
"The effects of isradipine and metoprolol were studied on the brachial arteries of two groups of 14 patients with hypertension, 90 minutes after the first dose and after 3 months of treatment."5.07Intrinsic effect of antihypertensive treatment with isradipine and metoprolol on large artery geometric and elastic properties. ( Brautigam, M; Del Pino, M; Levenson, J; Merli, I; Simon, A; Welzel, D, 1993)
"Obesity affects the efficacy of metoprolol and isradipine in reducing blood pressure."5.07Obesity as a determinant for response to antihypertensive treatment. ( Gatzka, C; Rüddel, H; Schächinger, H; Schmieder, RE; Schobel, H, 1993)
"The hypothesis that plasma lipids may modulate the antihypertensive effect of the calcium antagonist isradipine was tested in 85 patients who had essential hypertension."5.07Antihypertensive effect of the calcium antagonist isradipine and lipid profile. ( Farsang, C; Kapocsi, J; Kiss, I; Maklári, E; Török, E, 1993)
"5 mg of isradipine twice daily in patients with mild-to-moderate hypertension, as seen in general practice."5.07Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS). ( Magometschnigg, D, 1993)
"The objective of this study was to compare the tolerability of isradipine and felodipine in patients with mild-to-moderate hypertension."5.07A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group. ( Cutler, SA; Hammond, JJ, 1993)
"This open-label trial of isradipine was carried out in 3422 outpatients by 893 general practitioners to assess the efficacy, safety, and tolerability of isradipine as monotherapy in mild-to-moderate hypertension."5.07Efficacy, safety, and tolerability of isradipine in hypertension as used in general practice in a developing country (Pakistan). ( Hashmi, MS; Khan, AH; Samad, A, 1993)
"This multicenter, double-blind, randomized trial of 1 year's duration compared the safety and efficacy of isradipine, methyldopa, and placebo in 368 men, aged 40 to 65 years, with mild-to-moderate essential hypertension."5.07A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group. ( Cristal, N; Yodfat, Y, 1993)
" This study compared the pre- and post-treatment evaluations of 268 men with mild hypertension, aged 40 to 65 years, who were randomly allocated to three treatment groups (methyldopa, isradipine, and placebo) with that of 155 normotensive subjects."5.07Reexamining the quality of life of hypertensive patients. A new self-structured measure. ( Amir, M; Bar-On, D, 1993)
"The new slow-release oral formulation (SRO) of isradipine, a dihydropyridine calcium antagonist, was evaluated in 57 patients who had moderate-to-severe hypertension following a 2-week wash-out period and a 2-week placebo period."5.07Efficacy of slow-release oral isradipine in moderate-to-severe hypertension with add-on spirapril. ( Abarquez, RF; Castillo, RR; Sy, RG, 1993)
" Isradipine was used as first-line antihypertensive treatment in 15 patients who had mild-to-moderate hypertension and LVH, and who were studied before and after 6 months of treatment."5.07Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients. ( Antonopoulos, S; Athanasopoulos, G; Cokkinos, DV; Handanis, S; Kolovou, G; Manolis, AJ, 1993)
"The comparative efficacy of the calcium antagonists isradipine and nifedipine in reducing left ventricular peak systolic wall tension was assessed in 25 patients with essential hypertension (20 men, 5 women; mean age: 49 years)."5.07Effect of short-term antihypertensive therapy on left ventricular wall tension. A double-blind comparison of isradipine and nifedipine. ( Burger, KJ; Griebenow, R; Müller, R; Steffen, HM; Welzel, D, 1993)
"The objective of this study was to analyze the long-term hemodynamic effects of the calcium antagonist isradipine in mild hypertension compared with those of the beta 1-selective adrenoceptor antagonist atenolol, focusing in particular on the development of cardiac hypertrophy."5.07Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. ( Gleerup, G; Haedersdal, C; Mehlsen, J; Winther, K, 1993)
" Patients with essential hypertension were treated for 8 weeks with either nitrendipine (10 mg once daily) or isradipine (2."5.07Treatment of hypertension with calcium antagonists and aspirin. Effects on 24-h platelet activity. ( Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Trnovec, T; Ulicna, L, 1993)
" In a 1-year study, 32 patients with essential hypertension were randomized to treatment with either the converting enzyme inhibitor lisinopril or the calcium antagonist isradipine; hydrochlorothiazide could be added."5.07Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. ( Amery, AK; Bielen, EC; Fagard, RH; Lijnen, PJ; Tjandra-Maga, TB; Verbesselt, R, 1992)
"MIS is a one-year Multicentre Isradipine Study of the treatment of essential hypertension, in which participated seven centres in Czechoslovakia."5.07[Multicenter study of isradipine in the treatment of hypertension]. ( Balazovjech, I; Dzúrik, R; Fet'kovská, N; Kvasnicka, J; Lupínek, Z; Mayer, O; Pidrman, V; Widimský, J, 1992)
"One-year open Multicentric Isradipine Study (MIS) performed in 7 centres in Czechoslovakia included 144 patients with mild and moderate hypertension."5.07MIS (Multicentric Isradipine Study of antihypertensive therapy). ( Balazovjech, I; Dzúrik, R; Fetkovská, N; Kvasnicka, J; Lupínek, Z; Mayer, O; Pidrman, V; Widimský, J, 1992)
"The tolerability of isradipine was evaluated in an open trial of patients with mild-to-moderate essential hypertension as treated in general practice."5.07Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance study. ( Bara, L; Bogaert, M; De Keyser, P; Degaute, JP; Hermans, L; Lanssiers, P; Rorive, G; Six, R; Westelinck, KJ, 1992)
"At the end of a short-term (3-month) study of antihypertensive treatment of mild-to-moderate hypertension, 141 of the 200 study patients continued into a 2-year follow-up of isradipine as monotherapy or in combination with other antihypertensive agents."5.07Long-term (2-year) isradipine data in the treatment of mild-to-moderate hypertension. ( Clement, DL; D'Hont, G; De Keyser, P; Hermans, L; Meurant, JP; Rorive, G; Westelinck, KJ, 1992)
"A short-term trial of isradipine was conducted to assess its effectiveness and tolerability in the treatment of mild-to-moderate hypertension."5.07Isradipine in the treatment of mild-to-moderate hypertension in Portugal. ( Correa-Nunes, A; Mariano-Pego, G; Pereira-Miguel, JM; Rocha-Gonçalves, F, 1992)
"The clinical efficacy and tolerability of isradipine was evaluated in 63 patients with mild-to-moderate hypertension [supine systolic blood pressure (SBP) greater than or equal to 160 mm Hg and diastolic blood pressure (DBP) greater than or equal to 95 mm Hg]."5.07Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients. ( Armaganijan, D; Batlouni, M; Ghorayeb, N; Magliano, MF, 1992)
"The effects of the calcium antagonist isradipine and the beta-blocker metoprolol, which are based on different antihypertensive therapeutic principles, were evaluated in 52 men with mild-to-moderate hypertension in a 6-week, double-blind, randomized study."5.07Pharmacological modulation of stress-induced cardiovascular hyperreactivity in essential hypertension. ( Bräutigam, M; Rüddel, H; Schächinger, H; Schmieder, R; Schulte, W; Welzel, D, 1992)
"The safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and normal or slightly impaired renal function."5.07Effects of isradipine on hypertension and renal hemodynamics. ( Dardamanis, M; Elisaf, M; Pappas, M; Sferopoulos, G; Siamopoulos, KC, 1992)
"Fourteen women with hypertension of pregnancy and who were in their last trimester were subjected to three standardized physical stress tests before and after 1-2 weeks of treatment with 5 mg of isradipine twice daily."5.07Effect of isradipine on responses to standardized physical stress tests in hypertension of pregnancy. ( Grunewald, C; Lunell, NO; Nisell, H, 1992)
"In a randomized trial, a calcium antagonist, isradipine (ISR) and sodium nitroprusside (SNP) were compared in the management of hypertension in the early period following coronary artery bypass grafting (CABG)."5.07Isradipine for the treatment of hypertension following coronary artery bypass graft surgery: a randomized trial versus sodium nitroprusside. ( David, D; Loria, Y; Ruegg, PC, 1992)
"The components of blood flow resistance were investigated in 14 men with essential hypertension (diastolic blood pressure higher or equal to 100 mm Hg) before and after treatment with the dihydropyridine calcium antagonist-isradipine."5.07Flow resistance and its components in hypertensive men treated with the calcium antagonist isradipine. ( Andersson, OK; Bagge, U; Persson, B; Wysocki, M, 1992)
"Sixteen middle-aged men with primary hypertension were treated with the calcium antagonist isradipine over a 9-week period in a randomized, placebo-controlled, double-blind cross-over manner."5.07Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria. ( Andersson, OK; Hedner, T; Karlberg, B; Persson, B; Wysocki, M, 1992)
"In a double-blind, randomized trial with 26 male white patients with essential hypertension in World Health Organization Stages I and II, we examined the impact of calcium entry blockade (5 to 10 mg/day isradipine, N = 14) and beta-blockade (100 to 200 mg/day metoprolol, N = 12) on early markers of hypertensive nephropathy before and after 7 weeks' treatment."5.07Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. ( Rockstroh, J; Rüddel, H; Schächinger, H; Schlebusch, H; Schmieder, RE; Schulte, W, 1992)
"After three months of treatment with isradipine, 20 patients with mild hypertension had reduced their resting blood pressure (BP) from 157/103 to 132/85 mm Hg and their BP during isometric exercise from 192/124 to 166/105 mm Hg."5.07Antihypertensive effect of isradipine on blood pressure at rest and during exercise. ( Blaha, M; Dvorák, I; Nĕmcová, H, 1991)
"In this study of the efficacy and safety of isradipine as first-line therapy in hypertension, 1,647 patients enrolled; 1,472 completed the 4-week placebo run-in period and began treatment with isradipine at 2."5.07Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society. ( Lüscher, TF; Waeber, B, 1991)
"The antihypertensive effects of isradipine and captopril were studied in 231 patients with mild-to-moderate hypertension in a double-blind, randomized, between-patient trial."5.07Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension. ( Fitscha, P; Hitzenberger, G; Meisner, W, 1991)
"The efficacy and safety of isradipine and nifedipine retard were compared in 51 patients with mild-to-moderate essential hypertension."5.07First clinical experience with isradipine in the treatment of hypertension in Portugal. ( Botelho, MA; Correia, JM; Mariano-Pego, G; Rocha-Gonçalves, F; Viegas, J, 1991)
"The antihypertensive effect of isradipine compared with placebo was assessed in 28 male patients (aged 40-64 years) with mild-to-moderate essential hypertension."5.07The antihypertensive action of isradipine in mild essential hypertension. ( Farragi, D; Laszt, A; Viskoper, JR, 1991)
"This was a double-blind multicenter study to compare the efficacy, tolerability and effects on the quality of life with isradipine and atenolol in the treatment of essential hypertension."5.07Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group. ( Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Kullman, S; Scherstén, B; Sivertsson, R; Sörensen, S, 1991)
"A total of 203 patients with hypertension (supine diastolic blood pressure of 100-119 mm Hg) from six centers entered into a 3-week placebo baseline followed by 5 weeks of active treatment (either placebo or isradipine 2."5.07Assessment of electrocardiographic ischemia in hypertensive patients treated with isradipine or placebo. ( Carr, AA; Prisant, LM, 1991)
"The Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) is a randomized, double-blind, active-control trial to compare the effectiveness of two treatment regimens for the control of hypertension in reducing the rate of progression of early extracranial carotid artery atherosclerosis in hypertensive patients."5.07MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data. ( Applegate, WB; Byington, RP, 1991)
"Isradipine, a new antihypertensive dihydropyridine calcium antagonist, was evaluated for its efficacy, tolerability, and safety in 91 ambulatory patients who had mild-to-moderate hypertension."5.07Multicenter evaluation of efficacy, tolerability and safety of a new first-line antihypertensive drug, isradipine, in a Latin-American population. ( Acevedo, L; Gamarra, G; Gómez, G; Izurieta, A; Melgarejo, E; Narváez, J; Restrepo, G, 1991)
"The antihypertensive effects of isradipine and captopril were studied in 140 patients (70 men) with mild-to-moderate hypertension, aged 26 to 74 years, in a double-blind, randomized, between-patient comparative trial."5.07Antihypertensive effects of isradipine and captopril as monotherapy or in combination. ( Fitscha, P; Hitzenberger, G; Meisner, W, 1991)
"This multicenter trial compared the efficacy and safety of isradipine and enalapril in 160 patients with essential hypertension."5.07A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension. ( Eisner, GM; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR; Vargas, R; Zemel, M, 1991)
"The hypotensive effect of isradipine was assessed in 26 male patients, aged 40 to 64 years, with hypertension."5.07Twenty-four-hour blood pressure control with isradipine in mild essential hypertension. ( Faraggi, D; Laszt, A; Viskoper, JR, 1991)
"In one study of 10 patients with mild-to-moderate hypertension, equivalent total daily doses (13 +/- 2 mg) of isradipine given twice daily and a modified-release formulation of isradipine (isradipine MR) given once daily were found to control adequately 24 h ambulatory blood pressure compared with placebo (P less than ."5.07Low-dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension. ( Beekman, J; de Bruijn, JH; Diemont, WL; Hagels, G; Siegers, AM; Stegeman, CJ, 1991)
"The objective of the study was to investigate the effect of isradipine on red blood cell filtrability in 20 men with mild-to-moderate hypertension."5.07Effect of isradipine on factors affecting blood viscosity. ( Cristal, N; Paran, E; Slonim, A, 1991)
"The effect of the calcium antagonist isradipine on platelet aggregation (induced ex vivo by serotonin and low-density lipoprotein [LDL]) was studied in 17 nonsmoking patients with essential hypertension."5.07Platelet-activating effect of low-density lipoprotein and its reversal by isradipine. ( Dzúrik, R; Fedelesová, V; Fetkovská, N; Kozlovský, M, 1991)
"The objective of the study was to assess the effects of the calcium antagonist isradipine on plasma lipids, lipoproteins, and apolipoproteins in patients with essential hypertension."5.07Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients. ( Brun, D; Dion, D; Gagné, C; Lacourcière, Y; Poirier, L; Yardley, C, 1991)
"This was a study of the effectiveness of isradipine, a calcium antagonist of the dihydropyridine group, in reversing left ventricular hypertrophy (LVH) in patients with mild-to-moderate hypertension."5.07Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine. ( Abreu, P; Ajzen, H; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Vanneta, A, 1991)
"The renal effects of a single oral dose of placebo v a new dihydropyridine calcium antagonist, isradipine, were investigated in 12 patients with mild-to-moderate essential hypertension."5.07Acute antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function. ( Rosenfeld, JB; Wittenberg, C, 1991)
"9 years) who had developed hypertension (blood pressure greater than 140/90 mm Hg) took part in an open pilot study with the new calcium antagonist isradipine."5.07Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy. ( Feiks, A; Grünberger, W; Meisner, W, 1991)
"Isradipine, a new calcium channel blocker, was given to 32 patients with mild to moderate essential hypertension."5.07A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients. ( Christensen, HR; Kampmann, JP; Simonsen, K, 1991)
"Hemodynamic Effects of Isradipine and Nifedipine in Hypertension Myocardial wall tension is an important determinant of the oxygen demand, the function and the degree of hypertrophy of the left ventricle."5.07[The hemodynamic effects of isradipine and nifedipine in hypertension]. ( Burger, KJ; Distler, GA; Gross, P; Koppenhagen, K; Welzel, D; Wudel, E, 1991)
"The new calcium antagonist isradipine was compared with nifedipine retard in a multicenter, double-blind, placebo-controlled, randomized study involving 159 patients with mild hypertension."5.06Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine. ( Burger, KJ; Weidinger, G; Welzel, D, 1990)
"The objectives of this study were (a) to evaluate the dose-response effect of isradipine, a dihydropyridine calcium antagonist, on the heart rate and blood pressure of males with mild to moderate hypertension; and (b) to compare these results with those obtained with propranolol, a beta-adrenoceptor blocker, on a matched patient population."5.06Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol. ( Cantor, A; Cristal, N, 1990)
"Seventeen middle-aged males with sustained essential hypertension (WHO stage II) and diastolic blood pressures (BP) exceeding 100 mm Hg during a placebo run-in period completed a trial to assess the hemodynamic effects of isradipine, a new dihydropyridine calcium antagonist."5.06Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist. ( Andersson, OK; Persson, B; Widgren, BR; Wysocki, M, 1990)
" Therefore, the effects of isradipine, a new calcium antagonist, on glucose tolerance and insulin secretion during a 75-g oral glucose tolerance test (OGTT) and on ADP- and collagen-induced maximum first-wave platelet aggregation (Tmax%) were studied in 11 type II diabetic patients with borderline hypertension."5.06Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. ( Gisinger, C; Klauser, R; Prager, R; Schernthaner, G; Speiser, P, 1990)
"The antihypertensive effect and safety of treatment of hypertension with isradipine, a Ca antagonist of dihydropyridine group in monotherapy and in combination with the betablocker bopindolol was assessed in a multicentre study joined by six Czechoslovak centres."5.06Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives. ( Dvorák, I; Dzúrik, R; Fetkovská, N; Jonás, P; Kotlík, I; Markuljak, I; Petr, P; Widimský, J, 1990)
"Treatment with the new calcium antagonist isradipine significantly reduced diastolic blood pressure to less than 90 mm Hg in 64% of fourteen blacks with mild or moderately severe essential hypertension."5.06The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients. ( Carr, AA; Prisant, LM, 1990)
"In conjunction with a multicentre clinical trial of the calcium antagonist isradipine in hypertension, pharmacokinetic and pharmacodynamic studies were conducted in 9 subjects."5.06The pharmokinetics of isradipine in hypertensive subjects. ( Boutagy, J; Dunagan, F; Rumble, F; Shenfield, GM; Stokes, GS, 1990)
" After a 3-week placebo washout period, 21 ambulatory subjects with mild hypertension (mean age, 57 years; 67% men; 76% white) randomly received isradipine or enalapril twice daily in a double-blind titration during 10 weeks."5.06Improved compliance measures: applications in an ambulatory hypertensive drug trial. ( Ahmed, S; Barton, C; Bonduelle, D; Rudd, P; Zachary, V, 1990)
"Isradipine, a new calcium antagonist, was administered to 51 Pakistani patients with hypertension (36 women, 15 men; mean age 47 years) over an 8-week period."5.06Isradipine in Asian patients with hypertension. ( Hussain, S; Karim, S; Zubair, M, 1990)
"The effective and well tolerated dose of isradipine was determined in 130 Filipino patients with mild to moderate essential hypertension in a multicentre study with a 2-week placebo pretreatment period followed by an 8-week active treatment period."5.06Isradipine dose-confirmation study in Filipino patients with mild to moderate hypertension. ( Abarquez, RF; Anastacio, RV; Cabral, EI; Calleja, HB; Castillo, RR; Divinagracia, RA; Namin, EP; Porciuncula, CI, 1990)
"The calcium antagonists of the dihydropyridine group, isradipine and nifedipine, were compared in 64 patients with mild to moderate hypertension (diastolic blood pressure 95 to 110mm Hg)."5.06The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine. ( Burger, KJ; Welzel, D, 1990)
"In this double-blind cross-over study 16 patients with mild-to-moderate hypertension were treated with placebo and the dihydropyridine derivative, isradipine 5-10 mg twice daily."5.06Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension. ( Amery, A; Devos, P; Fagard, R; Hespel, P; Lijnen, P; Staessen, J; Tan, WP, 1989)
"The long-term effects (9 weeks) on renal hemodynamics of the new calcium entry blocker isradipine (PN 200-110) were assessed in 20 middle-aged male patients with essential hypertension."5.06Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension. ( Andersson, OK; Persson, B; Wysocki, M, 1989)
"One hundred eighteen patients, aged between 65 and 87 years with mild-to-moderate hypertension were given placebo or isradipine (1."5.06Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group. ( , 1989)
"A total of 152 patients with essential hypertension (World Health Organization classification I/II) entered a multicenter randomized study to assess the safety and efficacy of isradipine compared with, and in combination with, the beta-blocker atenolol."5.06A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group. ( , 1989)
"The effects of combined treatment with the calcium antagonist isradipine and the angiotensin-converting enzyme inhibitor captopril were investigated in a randomized, placebo-controlled parallel-group trial comprising 28 patients with essential hypertension."5.06Additive effect of isradipine in combination with captopril in hypertensive patients. ( Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1989)
"In a double-blind parallel-group randomized study, 28 patients with essential hypertension (World Health Organization class I/II) were allocated in equal numbers to one of two groups for treatment with either isradipine 5 to 20 mg twice daily or atenolol 50 to 100 mg once daily."5.06Differential effects of isradipine and atenolol on peripheral hemodynamics and arterial compliance. ( Jespersen, LT; Krusell, LR; Pedersen, OL; Sihm, I, 1989)
"Twenty-three men with essential hypertension participated in a double-blind placebo-controlled study with a crossover design to evaluate the long-term (nine weeks) effects of isradipine on central and renal hemodynamics."5.06Renal and hemodynamic effects of isradipine in essential hypertension. ( Andersson, OK; Aurell, M; Hedner, T; Persson, B; Wysocki, M, 1989)
"One hundred seventy-eight patients, aged 30 to 85, with mild-to-moderate hypertension entered a multicenter double-blind, randomized, between-patient comparison of isradipine (0."5.06Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group. ( , 1989)
"Six hundred outpatients aged between 22 and 84 years with essential hypertension (diastolic blood pressure of at least 95 mm Hg) entered a multinational, multicenter, single-blind trial with dose titration to assess the safety, tolerability, and efficacy of isradipine in doses of 1."5.06A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension. ( Keller, A; Rüegg, PC; Sundstedt, CD; Waite, R, 1989)
"Twenty-three middle-aged men (59 +/- 2 years) with sustained, essential hypertension (WHO Stage II) and with diastolic blood pressure exceeding 100 mmHg during a run-in placebo month were included in a trial designed to assess the clinical and haemodynamic effects of isradipine, a novel dihydropyridine calcium antagonist."5.06Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men. ( Andersson, OK; Aurell, M; Hedner, T; Persson, B; Wysocki, M, 1989)
"The effects of acute calcium entry blockade by isradipine (IS) and placebo (P) on the haemodynamic and humoral responses to angiotensin II (A II) have been compared in two groups of 9 patients with essential hypertension."5.06Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II. ( Amery, A; Fagard, R; Hespel, P; Lijnen, P; Moerman, E; Staessen, J, 1989)
"Isradipine (Sandoz PN 200-110), a new dihydropyridine calcium channel antagonist, was evaluated in a randomized, double-blind, placebo-controlled trial for antihypertensive efficacy in 24 patients with essential hypertension."5.06Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. ( Nelson, EB; Pool, JL; Taylor, AA, 1986)
"The safety and antihypertensive efficacy of PN 200-110 (isradipine), a novel calcium antagonist, are discussed in a preliminary report of double-blind, multicenter, controlled, phase III clinical trials for essential hypertension."5.06Treatment of essential hypertension with PN 200-110 (isradipine). ( Hamilton, BP, 1987)
"The long-term efficacy of isradipine, a new dihydropyridine calcium antagonist with marked vascular selectivity, was evaluated in 17 patients with essential hypertension."5.06The long-term effect of isradipine in pindolol-treated patients. ( Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Svensson, A, 1987)
"The effects of 10 weeks of treatment with isradipine (ISRP), a new dihydropyridine Ca antagonist, was evaluated in a prospective, randomized, double-blind, parallel group, hydrochlorothiazide (HCTZ) controlled study in patients with mild to moderate hypertension."5.06Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study. ( Gonasun, LM; Goodman, RP; Kirkendal, WM; Kontos, HA; Mohanty, PK; Samuel, P; Wright, JT, 1988)
" Extended-release nifedipine and amlodipine are the two most commonly used oral CCAs in the management of pediatric hypertension."4.83A review of calcium channel antagonists in the treatment of pediatric hypertension. ( Sahney, S, 2006)
"A meta-analysis was performed to compare the risk of serious adverse events associated with the use of all formulations of isradipine, when used as monotherapy in hypertension, to active drug or placebo controls."4.79Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis. ( Allen, IE; Arellano, FM; Kumashiro, M; Kupelnick, B; Mohanty, N; Ross, SD, 1997)
"Isradipine is a dihydropyridine calcium antagonist used for the treatment of hypertension."4.78Cardiac effects of isradipine in patients with hypertension. ( Lund-Johansen, P, 1993)
" A MEDLINE search was conducted using the following indexing terms: isradipine, calcium-channel blockers, hypertension, and angina pectoris."4.78Isradipine--another calcium-channel blocker for the treatment of hypertension and angina. ( Lopez, LM; Santiago, TM, 1992)
"Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race."4.78Isradipine: overall clinical experience in hypertension in the United States. ( Miller, H, 1990)
"Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race."4.78Isradipine: overall clinical experience in hypertension in the United States. ( Miller, H, 1991)
"The objective of the present paper is to formulate nanostructured lipid carriers (NLCs) of a calcium channel blocker, isradipine, to enhance its oral bioavailability and prolong its antihypertensive effect apart from evaluating efficacy of the formulation in isoproterenol induced myocardial infarction in rats."4.12Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction. ( Alam, T; Ali, J; Ansari, MA; Baboota, S, 2022)
"9 years), at the dosage of 5 mg once a day."3.78[Metabolic tolerance of isradipine. Evaluation after three months of therapy]. ( Bernardini, A; Capone, A; Panuccio, D; Trabatti, MR, 1995)
"Isradipine is a potent dihydropyridine calcium channel blocker."3.77Isradipine. ( Schachter, M, 1991)
"5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome."3.73Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. ( Sirotiaková, J; Widimský, J, 2006)
"A 21-year-old white man, with propionic acidemia and seizures treated with phenytoin and carbamazepine, was started on isradipine for essential hypertension."3.71Phenytoin/isradipine interaction causing severe neurologic toxicity. ( Cachat, F; Tufro, A, 2002)
"Isradipine is an effective, orally administered agent for control of hypertension in children."3.70Initial experience with isradipine for the treatment of hypertension in children. ( Groshong, T; Strauser, LM; Tobias, JD, 2000)
"Fifty patients with stable slight and moderate uncomplicated essential hypertension, treated by ramipril, atenolol, or isradipine, were examined."3.70[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension]. ( Betekhtina, VA; Rakov, SS, 2000)
" The effect of the antihypertensive calcium antagonist isradipine on the "Windkessel" function of the aorta was measured in terms of the central haemodynamics in ten patients (eight men, two women; mean age 58 +/- 3 years) with essential hypertension (WHO stage I-II) before and 3 months after treatment."3.69[The compliance of the large elastic arteries after blood pressure-lowering therapy with a calcium antagonist]. ( Messerli, FH; Schmieder, RE, 1995)
" With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity."3.69[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995)
"The effect of regression of left ventricular hypertrophy was studied in deoxycorticosterone-acetate-salt hypertensive rats (DOCA-salt hypertensive rats) treated with tetrandrine."3.69Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. ( Rao, MR; Xu, Y, 1995)
"The influence of hypertension and of treatment with the dihydropyridine calcium channel blocker isradipine on the morphology of the thoracic aorta and of the aortic tunica intima were studied."3.69Effect of long term isradipine treatment on the morphology of the endothelium in the aorta of spontaneously hypertensive rats. ( Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1994)
"To investigate the influence of hypertension and of treatment with the vasodilator hydralazine or with the dihydropyridine calcium antagonist isradipine on the morphology of the thoracic aorta in spontaneously hypertensive rats (SHR)."3.69Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats. ( Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1994)
"To determine the appropriate dosage regimen of isradipine in black patients with severe hypertension of pregnancy, 10 patients (gestational age, 30 to 38 weeks; diastolic blood pressure [DBP], 110 to 148 mm Hg; no hypertensive crises; and normal central venous pressure) were given an isradipine infusion while the fetal heart rate was continuously recorded using a cardiotocograph."3.69Intravenous isradipine in the management of severe hypertension in pregnant and nonpregnant patients. A pilot study. ( Khedun, SM; Madhanpall, N; Maharaj, B; Moodley, J; van der Byl, K, 1994)
" We attempted to verify the effectiveness of a new calcium antagonist, isradipine 5 mg SRO, on the reversal of left ventricular hypertrophy."3.69Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy. ( Baraldi, P; Masciocco, G; Mattioli, G; Modena, MG; Rossi, R, 1994)
"The purpose of this study was to ascertain if Isradipine treatment in spontaneously hypertensive rats (SHR) decreased hypertension-dependent left ventricular and coronary vascular hypertrophy."3.69Influence of isradipine treatment on left ventricular and coronary vascular hypertrophy in spontaneously hypertensive rats. ( Amenta, F; Ferrante, F, 1994)
"The antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement."3.69Indication for antihypertensive treatment: superiority of ambulatory vs casual blood pressure measurement. ( Fitscha, P; Meisner, W, 1994)
"The aim of our study was to investigate the effects of exercise on albuminuria and blood pressure in patients with essential hypertension, and the short-term effect of the calcium channel blocker isradipine on exercise-induced albuminuria (UAE) and blood pressure in the same patients."3.68Isradipine decreases exercise-induced albuminuria in patients with essential hypertension. ( Bossoni, S; Giustina, A; Macca, C; Romanelli, G, 1993)
"The present study was designed to investigate the influence of hypertension and of long-term treatment with the dihydropyridine calcium antagonist isradipine on the morphology of the femoral artery in spontaneously hypertensive rats (SHR)."3.68Structural changes in the endothelium of the femoral artery of spontaneously hypertensive rats: sensitivity to isradipine treatment. ( Abbate, F; Amenta, F; Ciriaco, E; Ferrante, F; Laurà, R, 1993)
"The authors demonstrated that isradipine reduces the blood pressure assessed at rest in patients with mild to medium severe hypertension."3.68[The antihypertensive effect of isradipine and additional pharmacodynamic effects]. ( Mayer, O; Polívková, H, 1993)
"The effects of isradipine on ambulatory blood pressure, platelet aggregation, and oxygen free radicals were assessed in 30 patients with hypertension in a non-comparative 16-week study."3.68Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension. ( Chou, TC; Ding, YA; Han, CL; Lai, WY; Shiao, MF, 1992)
"Lipid profiles were determined in 56 elderly patients with benign essential hypertension during an open-label 1-year study of the safety and efficacy of isradipine, a new calcium antagonist, in controlling blood pressure."3.68Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients. ( Bannatyne, RE; Lopez, L; Matthews, K; McCarley, D; Quay, G; Stein, GH, 1990)
"The effect of the calcium antagonist isradipine on serotonin metabolism and platelet aggregation was studied in 17 patients with essential hypertension."3.68Serotonin and platelet activation during treatment with isradipine. ( Dzurik, R; Fedelesova, V; Fetkovska, N; Sebekova, K, 1991)
"To assess the effect of isradipine on blood pressure, and uteroplacental and fetal blood flows in pregnancy-induced hypertension, 41 women with a diastolic blood pressure greater than or equal to 95 mm Hg were included in our study."3.68Isradipine, a new calcium antagonist: effects on maternal and fetal hemodynamics. ( Garoff, L; Grunewald, C; Lunell, NO; Nisell, H; Nylund, L; Sarby, B; Thornström, S, 1991)
"To evaluate the efficacy and duration of action of iv isradipine in the control of postoperative hypertension immediately after myocardial revascularization."3.68Isradipine for treatment of acute hypertension after myocardial revascularization. ( Alpern, J; Barnette, RE; Brister, NW; McClurken, JB; Schartel, SA, 1991)
"The immediate and short-term cardiovascular effects of oral isradipine therapy were evaluated in 11 patients with mild to moderate systemic hypertension."3.68Cardiovascular effects of isradipine in essential hypertension. ( Garavaglia, GE; Grossman, E; Messerli, FH; Nunez, B; Oren, S, 1991)
"In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler echocardiographic data to investigate the antihypertensive and hemodynamic effects of isradipine 5 mg in the new slow-release oral (SRO) formulation administered once daily for 12 weeks to 10 patients with mild to moderate hypertension."3.68Slow-release isradipine in mild to moderate hypertension: hemodynamic and antihypertensive effects. ( Celentano, A; de Divitiis, O; de Simone, G; Galderisi, M; Garofalo, M; Mureddu, GF; Tammaro, P, 1991)
"In view of the possibility that cardiac hypertrophy may be reversed by isradipine, we studied the effect of two different doses of isradipine (1."3.67Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine. ( Amorim, MP; Cezaretti, ML; de Almeida, JB; Portela, J; Ramos, OL; Saragoça, MA, 1989)
"Mean isradipine dose was 0."2.70Isradipine treatment of hypertension in children: a single-center experience. ( Flynn, JT; Warnick, SJ, 2002)
" Similar results were obtained when spirapril was combined with 5 mg isradipine in the initial and final single dose, or in the 3 months' treatment (5 mg o."2.69Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. ( Boner, G; Erman, A; Rosenfeld, J; Shohat, J; Wittenberg, C, 1999)
" Twice daily dosing of isradipine was associated with partial and significant restoration of the nocturnal decrease in blood pressure (systolic blood pressure decreased 5."2.69Hypertension after liver transplantation: a predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations. ( Canzanello, VJ; Krom, RA; Porayko, MK; Schwartz, L; Taler, SJ; Textor, SC; Wiesner, RH, 2000)
"Untreated essential hypertension is associated with left ventricular hypertrophy (LVH) and structural changes in resistance vessels."2.68Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. ( Aalkjaer, C; Holm, M; Lederballe, O; Mulvany, M; Mørn, B; Schroeder, AP; Sihm, I; Thygesen, K, 1995)
"Left ventricular hypertrophy is a common clinical feature in hypertensive patients and may be associated with structural changes in vessel morphology."2.68Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. ( Heagerty, AM; Kenedi, P; Rietbrock, N; Stephens, N; Thürmann, PA; Weidinger, G, 1996)
"Treatment with isradipine SRO 5 mg/day administered between 8 and 9 AM was started."2.68Analysis of blood pressure rhythms for drug efficacy evaluation. ( Angotti, S; Bravo, S; Codispoti, P; Damiani, S; Federico, L; Germanò, G; Muscolo, M, 1996)
"001) than patients treated with any of the monotherapies or with methyldopa in combination with captopril."2.68Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. ( Amir, M; Bar-On, D; Cristal, N; Yodfat, Y, 1996)
"Isradipine has a beneficial effect on in-vivo platelet function as evidenced by a decreased platelet deposition on vascular lesion sites and an associated prolonged platelet survival in patients with hypertension and active atherosclerotic lesions."2.68Effect of isradipine on in-vivo platelet function. ( Kritz, H; O'Grady, J; Pirich, C; Schmid, P; Sinzinger, H, 1997)
" In patients whose blood pressure was not normalized (defined as DBP< or =90 mmHg) after 6 weeks of treatment, the dosage of either medication was doubled or, in the placebo group, was switched to the fixed combination."2.68Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. ( Antlsperger, A; Pittrow, DB; Schardt, W; Wambach, G; Weidinger, G; Welzel, D, 1997)
" The side-effect score for edema was lower with ISR plus diuretics than with other combinations, whereas the ACE inhibitor was associated with a higher score for cough."2.67Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. ( Lüscher, TF; Waeber, B, 1993)
" Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs."2.67At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. ( De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994)
" The dosage was titrated if necessary after 4 weeks of treatment."2.67Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension. ( Chan, TY; Critchley, JA; Or, KK; Sanderson, JE; Tomlinson, B; Woo, J, 1994)
" In conclusion, treatment with dihydropyridines alone or in combination with low-dose aspirin can prevent circadian increases in platelet activity in patients with essential hypertension."2.67Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. ( Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L, 1994)
" The mean dosage was 1."2.67Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients. ( Correa-Nunes, A; Mariano-Pego, G; Moura, B; Pereira-Miguel, JM; Rocha-Gonçalves, F, 1994)
"Isradipine was given orally in parallel group design in plain and slow release formulations in doses of 2."2.67Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients. ( Christensen, HR; Kampmann, JP; Simonsen, K, 1993)
"SRO, given by oral route, in the dosage of 5 mg O."2.67[A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension]. ( Amodeo, C; Chaves, H; Francischetti, E; Jardim, PC; Lima Júnior, E; Magliano, MF; Mion Júnior, D; Nobre, F; Ribeiro, JM; Spritzer, N, 1993)
"On isradipine treatment these parameters remained unchanged."2.67A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. ( Christensen, P; Feldt-Rasmussen, B; Jensen, T; Nørgaard, K, 1993)
"Hypertension was treated with oral labetolol in combination with guanfacine if necessary."2.67Effect of isradipine on cyclosporin A-related hypertension. ( Ijzermans, JN; Schalekamp, MA; van den Dorpel, MA; Weimar, W; Zietse, R, 1994)
" During maintenance, patients not at goal were "stepped up," and patients with uncontrolled DBP at maximum dosage were removed from the study."2.67Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. ( Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994)
" Absolute DBP decrements versus placebo peaked 6 h after dosing (-8."2.67Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study. ( Arzilli, F; Borgnino, C; Caiazza, A; Del Prato, C; Gandolfi, E; Ghisoni, F; Giuntoli, F; Innocenti, P; Ponzanelli, F; Saba, P, 1993)
" The results of this study indicated that monotherapy with isradipine SRO at the recommended initial dosage of 5 mg once daily is appropriate in black patients with hypertension."2.67A comparative study of isradipine SRO and enalapril in black patients with mild-to-moderate hypertension. ( Maharaj, B; van der Byl, K, 1993)
" Both agents were able to achieve reductions in MAP to 80-90 mmHg quickly and safely, although the effects of isradipine at the dosage used were apparent sooner and gave smoother control than with sodium nitroprusside."2.67Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery. ( Chan, E; De Lange, S; Lawrence, CJ; Lestrade, A, 1993)
"5mg twice daily is effective, safe and tolerable in mild to moderate hypertension."2.67Efficacy, tolerability and safety of isradipine (Lomir) in the treatment of mild to moderate Tanzanian hypertensives. ( Lwakatare, JM; Maro, EE; Mtulia, IA, 1992)
"Isradipine was given sublingually in doses of 1."2.67Isradipine in the treatment of hypertensive crisis in ambulatory patients. ( Lotaif, L; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Ventura, RP, 1992)
"To evaluate the effects of short- and long-term administration of calcium (Ca) entry blockers on cardiovascular responses to cigarette smoking, 28 normotensive and 26 hypertensive smokers were studied."2.67Effects of calcium channel blockers on cardiovascular responses to smoking in normotensive and hypertensive smokers. ( Corradi, L; Fogari, R; Malamani, GD; Zoppi, A, 1992)
" No adverse reactions were reported by 68 percent of the patients in Group I and 65% of those in Group D."2.67A comparison of the safety of therapeutically equivalent doses of isradipine and diltiazem for treatment of essential hypertension. ( Abrams, AP; Black, HR; Hamilton, BP; Hamilton, JH; Isaacsohn, JL; Kochar, MS; Lewin, AJ; MacCarthy, EP; Madias, NE; Stein, GH, 1992)
"The antihypertensive efficacy and tolerability of the new calcium antagonist isradipine was assessed in 86 hypertensive patients who had pretreatment diastolic blood pressures (DBP) greater than or equal to 105 mm Hg and who were randomly allocated to a double-blind comparison of three different dosage regimens: 1."2.67Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. ( Burger, KJ; Kirch, W; Weidinger, G; Welzel, D, 1990)
"Hypertension is a risk factor for the development of atherosclerosis and its complications, which are among the major causes of morbidity and mortality."2.67The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group. ( Bond, MG; Borhani, NO; Buckalew, V; Canossa-Terris, M; Gibbons, ME; Sowers, JR; Worthy, AJ, 1991)
"The objective of this study was to compare the effects of isradipine and placebo on blood pressure (BP) at the end of the dosing interval ('trough')."2.67Isradipine twice daily lowers blood pressure over 24 H. ( de Zwart, P; Holmes, DG; Lasance, A; Man in't Veld, AJ, 1991)
"Aldosterone levels were also increased after three months, but without a subsequent decrease."2.67Isradipine in the treatment of hypertension. Some additional effects observed during a one-year study. ( Mayer, O; Polivkova, H; Rottenborn, J, 1991)
" The Montevideo Mathematical Model was used to determine the time course of the response to treatment in each dosage group."2.67Time course of the blood pressure response to oral isradipine in uncomplicated mild-to-moderate essential hypertension. ( Leary, WP; Maharaj, B; Reyes, AJ; van der Byl, K, 1991)
"It is concluded that treatment of hypertension with a compound that lowers blood pressure and inhibits platelet activation may be of clinical benefit when routinely applied in hypertensive patients."2.67Effects of isradipine on platelet function in hypertension at rest and during exercise. ( Fitscha, P; Rauscha, F; Sinzinger, H; Virgolini, I, 1991)
" The mean dosage in the isradipine group was 7."2.67Effect of isradipine and atenolol on lung function in patients with mild essential hypertension. ( Meisner, W; Reiterer, W, 1991)
"Isradipine was also well tolerated."2.67Management of perioperative hypertension using intravenous isradipine. ( Karmann, U; Keller, H; Rüegg, PC, 1991)
"Arterial hypertension is common after coronary artery-bypass grafting (CABG) surgery and may lead to postoperative complications."2.67Isradipine, a calcium antagonist, in the control of hypertension following coronary artery-bypass surgery. ( de Lange, S; Lawrence, CJ; Lestrade, A, 1991)
"The isradipine-treated ambulatory hypertensive group experienced significantly greater decreases in BP during 24-hour, work, awake and sleep periods than did the ambulatory normotensive group."2.67Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. ( Dion, D; Lacourcière, Y; Poirier, L; Provencher, P, 1990)
"The efficacy and safety of once-daily dosing of isradipine, a new calcium antagonist vasodilator, was evaluated in a multicenter, placebo-controlled trial in hypertensive patients who had supine diastolic blood pressure (SDBP) 100-119 mm Hg."2.67Placebo-controlled trial of once-a-day isradipine monotherapy in mild to moderately severe hypertension. ( Canosa, FL; Carr, AA; Cohen, M; Kirkendall, WM; Lewin, AJ; McMahon, FG; Winer, N, 1990)
"Isradipine is a new calcium antagonist of the dihydropyridine type, with marked vasodilator activity and minimum negative inotropic effects."2.67Multicentre isradipine dose-confirmation study in Thai patients with hypertension. ( Charoenlarp, K; Jaroonvesama, N; Koanantakul, B; Nontakanun, S; Tanomsup, S; Tantbirojn, P, 1990)
"Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis."2.66Efficacy and safety of isradipine in hypertension. ( Brockway, B; Carr, AA; Davidov, M; Gonasun, L; Hamilton, B; Hamilton, J; Prisant, LM; Schnaper, H; Shepherd, AM; Velasquez, M, 1989)
"Isradipine is a new calcium antagonist of the dihydropyridine type with marked vasodilator activity and minimal negative inotropic effects."2.66Improved blood pressure control with isradipine in hypertensive patients treated with pindolol. ( Aström, B; Dahlöf, B; Frithz, G; Hansson, L; Himanen, P; Sundstedt, CD; Tollin, C, 1989)
"Isradipine is a more specific treatment for post-aortocoronary bypass graft hypertension than nitroprusside because its systemic arterial dilating effect is associated with a minimum of other circulatory changes."2.66Use of isradipine in hypertension following coronary artery bypass surgery. ( Davies, SW; Feneck, RO; Lunnon, MW; Underwood, SM; Walesby, RK, 1989)
"Based on pooled data from three randomized placebo-controlled dose-finding studies in a total of 489 patients, the dose-response relationship for efficacy and adverse events was estimated, using the Michaelis-Menten equation: Effect = maximal effect multiplied by dose/constant plus dose."2.66Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. ( Simonsen, K; Sundstedt, CD, 1989)
"Isradipine has a favorable renal effect profile and also has several properties that meet the requirements of other patient populations where an extra measure of antihypertensive safety is required, such as diabetics, dialysis patients, and transplant recipients."2.39Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine. ( Frishman, WH, 1994)
" This requires that the antihypertensive agent chosen have a demonstrated safe profile."2.39Antihypertensive therapy with isradipine in patients with special safety concerns. ( Blecker, D, 1994)
" Compliance tends to fall as dosing frequency rises above once daily."2.38Partial compliance: implications for clinical practice. ( Rudd, P, 1993)
"The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed."2.38Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993)
"Isradipine is a new dihydropyridine-derived calcium antagonist."2.38Isradipine: a profile in essential hypertension. ( Hansson, L, 1993)
"Isradipine is a new dihydropyridine calcium antagonist with a high degree of selectivity for the coronary, cerebral, and skeletal muscle vasculature."2.38The place of isradipine in the treatment of hypertension. ( Man in't Veld, AJ, 1991)
"Isradipine is a calcium antagonist with marked vascular selectivity and, in practical terms, is devoid of cardiac effects."2.38Isradipine in hypertension. ( Hansson, L, 1990)
" Our studies have shown that this action is evident during the first 2 days of administration of a dihydropyridine, and then seems to disappear; however, a small negative sodium balance persists, an observation that accounts for the absence of any increase in bodyweight or fluid volumes with long term administration of calcium antagonists, despite their vasodilating action."2.38Natriuretic effects of calcium antagonists. Clinical implications. ( Leonetti, G; Zanchetti, A, 1990)
" The blood pressure-lowering effect of isradipine as monotherapy is dose dependent and has shown a greater efficacy than propranolol, hydrochlorothiazide, and prazosin, without an increase in adverse effects."2.38Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension. ( Dahlöf, B, 1989)
"It should be useful in the treatment of hypertension, and, considering its pattern of cardiac actions, perhaps also as an after-load-reducing agent for the treatment of heart failure."2.37Selective effects of PN 200-110 (isradipine) on the peripheral circulation and the heart. ( Hof, RP; Salzmann, R; Siegl, H, 1987)
"Isradipine was given for 12 weeks to 30 patients (16 men, 14 women, mean age 50."1.32[Isradipine-SRO: antihypertensive efficacy, central and peripheral hemodynamic effects in patients with hypertensive disease]. ( Bartieva, DM; Makolkin, VI; Podzolkov, VI, 2003)
"Isradipine treatment did not modify the vasodilating effect of sodium nitroprusside."1.30Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients. ( Ceravolo, R; Chello, M; Cuda, G; Iacopino, S; Maio, R; Mastroroberto, P; Mattioli, PL; Perticone, F; Ventura, G, 1999)
"Treatment with isradipine alone caused a sustained reduction in blood pressure (-22/-10 mm Hg, P < 0."1.29Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1994)
" This pilot study was conducted to determine the appropriate dosage regimen for isradipine in black patients with severe hypertensive disorders of pregnancy."1.29Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study. ( Khedun, SM; Madhanpall, N; Maharaj, B; Moodley, J; van der Byl, K, 1994)
"Isradipine 0."1.29Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients. ( Aass, H; Simonsen, S, 1993)
"Isradipine was orally administered once a day at a dose of 5 mg before the morning cyclosporin intake."1.28Lack of effect of isradipine on cyclosporin pharmacokinetics. ( Bourbigot, B; Codet, JP; Le Saux, L; Moal, MC; Morin, JF; Vernillet, L, 1992)
" The patients were divided in three groups according to the used dosage of Isradipine tablets by sublingual route."1.28[Treatment of hypertensive crisis in outpatients with sublingual isradipine]. ( Lotaif, LD; Plavnik, F; Portela, JE; Ramos, OL; Saragoça, MA; Ventura, RP, 1992)
" Dosage was increased from 2."1.28Isradipine treatment for hypertension in general practice in Hong Kong. ( Critchley, JA; Teoh, R; Tomlinson, B; Woo, J, 1992)
"Analysis of an antihypertensive drug trial, which involved measurements of blood pressure (BP) during visits to the clinic at a set time of day, showed that the initial dosage titration procedure had been inadequate in some patients."1.28Timing of blood pressure measurements in determining anomalies in duration of effect of an antihypertensive drug: assessment of isradipine. ( Boutagy, J; Dunagan, F; Johnston, HJ; Marwood, JF; Shenfield, GM; Stokes, GS, 1990)
" Dose-response curves reveal that isradipine is one of the most potent and efficacious representatives of this class of compounds, reducing the infarct size by more than 60%."1.28Prevention of stroke and brain damage with calcium antagonists in animals. ( Rudin, M; Sauter, A, 1991)
"Isradipine treatment normalized blood pressure values in SHR and significantly reduced the area occupied by the medial layer and the wall-to-lumen ratio in small and medium-sized, but not in large-sized, coronary artery branches."1.28Effect of long-term isradipine treatment on the hypertension-dependent changes in coronary arteries in spontaneously hypertensive rats. ( Amenta, F; Ferrante, F, 1991)

Research

Studies (346)

TimeframeStudies, this research(%)All Research%
pre-199042 (12.14)18.7374
1990's286 (82.66)18.2507
2000's15 (4.34)29.6817
2010's2 (0.58)24.3611
2020's1 (0.29)2.80

Authors

AuthorsStudies
Alam, T1
Ansari, MA1
Baboota, S1
Ali, J1
Qadri, GR1
Ahad, A1
Aqil, M1
Imam, SS1
Ali, A1
Miyashita, Y1
Peterson, D1
Rees, JM1
Flynn, JT2
Cachat, F1
Tufro, A1
Warnick, SJ1
Podzolkov, VI1
Bartieva, DM1
Makolkin, VI1
Darcie, S1
Leone, CR1
Calil, VM1
Prescinotti, EP1
Kahhale, S1
Zugaib, M1
Ganz, M1
Mokabberi, R1
Sica, DA1
Johnson, BA1
Wells, LT1
Roache, JD1
Wallace, C1
Ait-Daoud, N1
Wang, Y1
Widimský, J7
Sirotiaková, J1
Sahney, S1
Sihm, I6
Schroeder, AP3
Aalkjaer, C3
Holm, M2
Mørn, B2
Mulvany, M2
Thygesen, K3
Lederballe, O2
Casarini, DE1
Carmona, AK1
Plavnik, FL2
Zanella, MT1
Juliano, L1
Ribeiro, AB1
Rudd, P5
Perticone, F2
Pugliese, F1
Marcantonio, AM1
Cloro, C1
Maio, R2
Mattioli, PL2
Wide-Swensson, DH1
Ingemarsson, I2
Lunell, NO4
Forman, A1
Skajaa, K1
Lindberg, B1
Lindeberg, S1
Marsàl, K1
Andersson, KE1
Lacolley, P1
Ghodsi, N1
Glazer, E1
Challande, P1
Brissac, AM1
Safar, ME1
Laurent, S1
Schmieder, RE4
Messerli, FH3
Zewdu, W1
Habte, B1
Chrysant, SG4
Cohen, M5
Moiseev, VS1
Ivleva, AIa1
Kobalava, ZhD1
Johnson, BF2
Eisner, GM2
McMahon, FG4
Jain, AK1
Sowers, JR6
Xu, Y1
Rao, MR1
Lüscher, TF2
Waeber, B3
Huguet, F2
Brisac, AM1
Dubar, M1
Ingrand, P1
Piriou, A1
Celis, H1
Staessen, J4
Fagard, R4
Thijs, L3
Amery, A4
Skoularigis, J1
Weinberg, J1
Strugo, V1
Davis, J1
Skudicky, D1
Zambakides, C1
Sareli, P1
Gleerup, G5
Mehlsen, J2
Winther, K5
Frishman, WH1
Brogden, RN1
Sorkin, EM1
Hermans, L4
Deblander, A1
De Keyser, P4
Scheys, I1
Lesaffre, E1
Westelinck, KJ3
Vogt, M1
Motz, W1
Strauer, BE2
Ikeda, S1
Amano, Y1
Adachi-Akahane, S1
Nagao, T1
Ferrante, F5
Ciriaco, E3
Abbate, F3
Laurà, R3
Amenta, F5
Stein, GH4
Hamilton, BP4
Hamilton, JH3
Holtzman, JL2
Kirkendall, WM3
Abrams, A2
Neri, G2
Culter, R1
Matthews, K2
Galderisi, M2
Celentano, A2
Garofalo, M2
Tammaro, P2
Oliviero, M1
Petrocelli, A1
de Divitiis, O2
Tomlinson, B2
Woo, J3
Critchley, JA2
Or, KK1
Chan, TY2
Sanderson, JE1
Tison, P3
Ulicna, L3
Jakubovska, Z3
Oravcova, J3
Fetkovska, N7
Farsang, C2
Kapocsi, J2
Kiss, I2
Török, E3
Kerkovits, G1
Holló, J1
Jávor, T1
Maharaj, B5
Khedun, SM2
Moodley, J2
Madhanpall, N2
van der Byl, K5
Rocha-Gonçalves, F3
Moura, B1
Pereira-Miguel, JM2
Correa-Nunes, A2
Mariano-Pego, G3
Pedersen, OL5
Leslie, J1
Brister, N1
Levy, JH1
Yared, JP1
Marty, A1
Martin, H1
Hines, R1
Savino, J1
Blecker, D1
Dmitriev, VV2
Kurkova, KS1
Arabidze, GG2
Shklovskiĭ, VM1
Rogova, AN1
Metelitsa, TV2
Vizel', TG1
Lind, L1
Berne, C1
Pollare, T1
Lithell, H1
Croog, SH1
Elias, MF1
Colton, T1
Baume, RM1
Leiblum, SR1
Jenkins, CD1
Perry, HM2
Hall, WD2
Veglio, F1
Rabbia, F1
Melchio, R1
Chiandussi, L1
Modena, MG1
Masciocco, G1
Rossi, R1
Baraldi, P1
Mattioli, G1
Marty, J1
Christensen, HR3
Simonsen, K3
Kampmann, JP2
Magliano, MF2
Amodeo, C1
Mion Júnior, D1
Francischetti, E1
Lima Júnior, E1
Nobre, F1
Chaves, H1
Ribeiro, JM1
Spritzer, N1
Jardim, PC1
Nørgaard, K1
Jensen, T1
Christensen, P1
Feldt-Rasmussen, B1
Simon, A2
Merli, I2
Del Pino, M2
Bräutigam, M3
Welzel, D11
Burger, KJ10
Levenson, J2
Low, CJ1
Foy, SG1
Chaudhary, H1
Crozier, IG1
Baskaranathan, S1
Ikram, H1
Fitscha, P9
Meisner, W7
Borhani, NO4
Amir, M3
Cristal, N5
Bar-On, D3
Loidl, A1
van den Dorpel, MA1
Zietse, R1
Ijzermans, JN1
Schalekamp, MA1
Weimar, W1
Pirich, C3
Schmid, P3
Sinzinger, H6
Pesau, B1
Virgolini, I3
Hammond, JJ2
Cutler, SA2
Giustina, A1
Bossoni, S1
Macca, C1
Romanelli, G1
Bielen, E1
Aass, H1
Simonsen, S1
Anlauf, M1
Bignotti, M2
Gaudio, G2
Gorini, G1
Rinaldi, O1
Grandi, AM2
Venco, A2
Benz, JR1
Bartels, DW1
Kostis, JB1
Townsend, RR1
Due, DL1
Peng, A1
Sirgo, M1
Lohmann, FW1
Rolachon, A1
Bichard, P1
Kezachian, G1
Zarski, JP1
Grossman, E2
Oren, S2
Soria, F1
Guerrero, D1
Bryant-Kosling, C1
Middleton, B1
Middleton BF [corrected to Middleton, B]1
Lund-Johansen, P1
Gatzka, C1
Schächinger, H3
Schobel, H1
Rüddel, H3
Prisant, LM6
Zemel, PC1
Nichols, FT1
Zemel, MB1
Carr, AA7
Thompson, WO1
Bond, MG4
Arzilli, F1
Gandolfi, E1
Del Prato, C1
Innocenti, P1
Ponzanelli, F1
Caiazza, A1
Ghisoni, F1
Saba, P1
Giuntoli, F1
Borgnino, C1
Fogari, R2
Malacco, E1
Tettamanti, F1
Gnemmi, AE1
Milani, M2
Walton, T1
Symes, LR1
Gomis, R1
Vidal, J1
Novials, A1
Coves, MJ1
Parreira, JM1
Correia, LG1
Pereira, E1
Duarte, RS1
Pape, E1
Maklári, E1
Bondesson, U1
Grunewald, C3
Nisell, H3
Wide-Swensson, D1
Saragoça, MA7
Mulinari, RA1
Oliveira, AF1
Portela, J2
Melegari, D1
Ramos, OL7
Furberg, CD5
Byington, RP5
Gibbons, ME2
Magometschnigg, D1
Samad, A2
Khan, AH1
Hashmi, MS1
Yodfat, Y2
Holmes, DG2
Abarquez, RF2
Sy, RG1
Castillo, RR2
Vyssoulis, GP1
Karpanou, EA1
Pitsavos, CE1
Soulas, DK1
Toutouzas, PK1
Cassiolatto, JL1
Vanetta, AM1
Canziani, ME1
Abreu, P3
Ventura, RT1
Manolis, AJ2
Kolovou, G1
Handanis, S2
Athanasopoulos, G1
Antonopoulos, S1
Cokkinos, DV2
Griebenow, R1
Müller, R1
Steffen, HM1
Haedersdal, C1
Trnovec, T1
Hansson, L8
Lawrence, CJ2
Lestrade, A2
Chan, E1
De Lange, S2
Chen, MF1
Chen, CC1
Chen, WJ1
Wu, CC1
Liau, CS1
Lee, YT1
Mayer, O4
Polívková, H2
Ferrara, LA1
De Simone, G2
Iannuzzi, R1
Gaeta, I1
D'Orta, G1
Turco, S1
Guida, L1
Marotta, T1
Zanzi, P1
Guasti, L1
Abbott, K1
Smith, A2
Bakris, GL1
Panuccio, D1
Trabatti, MR1
Bernardini, A1
Capone, A1
Dehner, R1
Thürmann, PA1
Stephens, N1
Heagerty, AM1
Kenedi, P1
Weidinger, G4
Rietbrock, N1
Groshong, T2
Ranieri, G1
Filitti, V1
Andriani, A1
Bonfantino, MV1
Lamontanara, G1
Cavallo, A1
De Cesaris, R1
Germanò, G1
Federico, L1
Angotti, S1
Codispoti, P1
Muscolo, M1
Bravo, S1
Damiani, S1
Parik, T3
Allikmets, K3
Zilmer, K1
Vihalemm, T1
Kullisaar, T1
Teesalu, R3
Zilmer, M1
Maher, MJ1
Dworkin, LD1
Aramisova, RM1
El'garov, AA1
Madren, EM1
Touyz, RM1
Schiffrin, EL1
Epifanova, ON1
Rogoza, AN1
Mychka, VB1
McCarron, DA3
Weder, AB3
Egan, BM1
Krishna, GG1
Morris, CD1
Oparil, S1
Rendell, MS1
Shehan, MA1
Kahler, K1
Bailey, KL1
Eckermann, AJ1
Bursztyn, M1
Zelig, O1
Or, R1
Nagler, A1
Johnson, CE1
Jacobson, PA1
Song, MH1
O'Grady, J3
Kritz, H2
Westbrook, P1
Bednarczyk, EM1
Carlson, M1
Sheehan, H1
Bissada, NF1
Albrecht, T1
Dulce, MC1
Dulce, KK1
Gotzen, R1
Wolf, KJ1
Weir, MR3
Hall, PS1
Behrens, MT1
Flack, JM1
Papademetriou, V1
Gottdiener, JS1
Narayan, P1
Cushman, WG1
Zachariah, PK1
Gottdiener, PS1
Chase, GA1
Akopov, SE1
Simonian, NA1
Ross, SD1
Kupelnick, B1
Kumashiro, M1
Arellano, FM1
Mohanty, N1
Allen, IE1
Fagard, RH2
Staessen, JA1
Wysocki, M7
Andersson, OK7
Persson, B7
Bagge, U2
McPherson, J1
Taylor, M1
Mason, A1
Carney, S1
Gillies, A1
Pittrow, DB1
Antlsperger, A1
Wambach, G1
Schardt, W1
Pahor, M3
Psaty, BM1
Mulvany, MJ2
Pelttari, LH1
Hietanen, EK1
Salo, TT1
Kataja, MJ1
Kantola, IM1
Rodríguez Moreno, C1
Nesterov, IuI2
Ivanova, IV1
Gol'dberg, GA2
Canossa-Terris, M3
Cohen, JD2
Gunter, PA2
Lewin, AJ4
Mennella, RF2
Kirkegaard, LW2
Weinberger, MH2
Beldekos, D1
Haralabidis, G1
Hatzissavas, J1
Foussas, S1
Bresnahan, M1
Gavras, I1
Gavras, H1
Schwartzkopff, B1
Muravyov, AV2
Zaitsev, LG1
Muravyov, AA1
Yakusevich, VV2
Sirotkina, AM1
Craven, TE3
Shohat, J1
Wittenberg, C3
Erman, A1
Rosenfeld, J1
Boner, G1
Ceravolo, R1
Ventura, G1
Iacopino, S1
Cuda, G1
Mastroroberto, P1
Chello, M1
Pĭtre, M1
Gaudreault, N1
Santuré, M1
Nadeau, A1
Bachelard, H1
Salo, TM1
Kantola, I2
Voipio-Pulkki, LM1
Pelttari, L1
Viikari, JS1
Mason, RP1
Mason, PE1
Strauser, LM1
Tobias, JD1
Taler, SJ1
Textor, SC1
Canzanello, VJ1
Schwartz, L1
Porayko, MK1
Wiesner, RH1
Krom, RA1
De Rosa, ML1
Maddaluno, G1
Lionetti, F1
Di Palma, U1
Albanese, L1
Cardace, P1
Baiano, A1
Vigorito, C1
Rakov, SS1
Betekhtina, VA1
Madi-Jebara, S1
Khater-Rassi, D1
Yazigi, A1
Haddad, F1
Hayek, G1
Achkouty, R1
Antakly, MC1
Meiselman, HJ1
Zamishlayev, AV1
Morris, MJ2
Dufilho, MD1
Devynck, MA2
Vernillet, L1
Bourbigot, B1
Codet, JP1
Le Saux, L1
Moal, MC1
Morin, JF1
Lwakatare, JM1
Maro, EE1
Mtulia, IA1
Bielen, EC1
Lijnen, PJ1
Tjandra-Maga, TB1
Verbesselt, R1
Amery, AK1
Yamada, S1
Matsuoka, Y1
Kato, Y1
Kimura, R1
Inagaki, O1
Portela, JE4
Plavnik, F4
Ventura, RP2
Lotaif, LD1
Fasce, E1
Lecannelier, E1
Dzúrik, R5
Fet'kovská, N1
Balazovjech, I2
Kvasnicka, J2
Lupínek, Z2
Pidrman, V2
Hirsch, AT1
Dzau, VJ1
Cutler, SS1
Levenson, DJ1
Creager, MA1
Miller, ST1
Brugger, SB1
Schnaper, HW1
Khoury, S1
Flack, J1
Ding, YA2
Han, CL2
Chou, TC2
Lai, WY2
Shiao, MF2
Bogaert, M1
Degaute, JP1
Rorive, G3
Six, R1
Bara, L1
Lanssiers, P1
D'Hont, G1
Meurant, JP2
Clement, DL2
Batlouni, M1
Armaganijan, D1
Ghorayeb, N1
Meriç, M1
Gören, T1
Atilgan, D1
Eren, N1
Cubukçu, A1
Koylan, N1
Schulte, W2
Schmieder, R1
Lotaif, L1
Borbás, S1
Lengyel, M1
Zorándi, A1
Gross, P2
Koppenhagen, K2
Wudel, E2
Distler, GA2
Siamopoulos, KC1
Elisaf, M1
Dardamanis, M1
Sferopoulos, G1
Pappas, M1
Rosenfeld, JB2
Luomanmäki, K1
Inkovaara, J1
Hartikainen, M1
Helin, M1
Viikari, J1
Kataja, M1
Ekman, K1
Harjula, K1
Ruegg, PC3
David, D1
Loria, Y1
Lore, W1
Anjichi, GM1
Zoppi, A1
Malamani, GD1
Corradi, L1
Silagy, CA1
McNeil, JJ1
McGrath, BP1
Teoh, R1
Krusell, LR4
Jespersen, LT5
Thomsen, K3
Pedersen, EB1
Soret, P2
Poget, PN1
Brunner, HR1
Youssef, S1
Osman, L1
Sabbour, MS1
Ol'binskaia, LI1
Morozova, TE1
Vartanova, OA1
Rauscha, F2
Cléroux, J1
Yardley, C2
Marshall, A1
Coulombe, D1
Lacourcière, Y3
Hedner, T4
Karlberg, B1
Black, HR1
MacCarthy, EP1
Madias, NE1
Kochar, MS1
Abrams, AP1
Isaacsohn, JL1
Schlebusch, H1
Rockstroh, J1
Lopez, LM1
Santiago, TM1
Galletti, F1
Rutledge, A1
Triggle, DJ1
Dvorák, I2
Blaha, M1
Nĕmcová, H1
Kirch, W1
Miller, H3
Stokes, GS2
Shenfield, GM2
Johnston, HJ1
Marwood, JF1
Dunagan, F2
Boutagy, J2
Cantor, A1
Widgren, BR1
Bannatyne, RE1
Quay, G1
Lopez, L1
McCarley, D1
Klauser, R1
Speiser, P1
Gisinger, C1
Schernthaner, G1
Prager, R1
Buckalew, V1
Worthy, AJ1
Hitzenberger, G2
Ventura, R1
Vanneta, A2
Ajzen, H2
Sebekova, K1
Fedelesova, V2
Hjørting Hansen, E1
Garoff, L1
Nylund, L1
Sarby, B1
Thornström, S1
Viegas, J1
Correia, JM1
Botelho, MA1
Rauhala, E1
Erkinjuntti, M1
Mansury, L1
Viskoper, JR2
Laszt, A2
Farragi, D1
Jern, S3
Scherstén, B1
Kullman, S1
Sörensen, S1
Dahlöf, B8
Eggertsen, R4
Sivertsson, R1
Brister, NW1
Barnette, RE1
Schartel, SA1
McClurken, JB1
Alpern, J1
Applegate, WB1
Sauter, A2
Rudin, M2
Gómez, G1
Melgarejo, E1
Narváez, J1
Gamarra, G1
Restrepo, G1
Acevedo, L1
Izurieta, A1
Man in't Veld, AJ2
Lasance, A1
de Zwart, P1
Rottenborn, J1
Leary, WP2
Reyes, AJ1
Vargas, R2
Zemel, M1
Cihák, R2
Lefflerová, K2
Janský, P2
Faraggi, D1
Diemont, WL1
Stegeman, CJ1
Beekman, J1
Siegers, AM1
Hagels, G1
de Bruijn, JH1
Slonim, A1
Paran, E1
Kozlovský, M1
Schwinger, RH1
Böhm, M1
Erdmann, E1
Gagné, C1
Brun, D1
Poirier, L2
Dion, D2
Duprez, D1
De Backer, T1
De Pue, N1
De Buyzere, M1
Reiterer, W1
Feiks, A2
Grünberger, W2
Karmann, U1
Keller, H1
Nunez, B1
Garavaglia, GE1
Schachter, M1
Edouard, A1
Dartayet, B1
Ruegg, C1
Samii, K1
Christensen, KL2
Januszewicz, W1
Wocial, B1
Chodakowska, J1
Feltynowski, T1
Lapiński, M1
Miguel, JM1
Nunes, AC1
Gonçalves, FR1
Pêgo, GM1
Mureddu, GF1
Bentahila, S1
Atkinson, J1
Capdeville, C1
Jonás, P1
Markuljak, I1
Petr, P1
Kotlík, I1
Provencher, P1
Rumble, F1
Samuel, P3
Soland, FX1
Graudal, N1
Cutler, R1
Hamilton, B2
Matthews, KP1
Winer, N3
Canosa, FL1
Ahmed, S1
Zachary, V1
Barton, C1
Bonduelle, D1
Abetel, G1
Karly, M1
Zanchetti, A2
Leonetti, G2
Tanomsup, S1
Tantbirojn, P1
Koanantakul, B1
Nontakanun, S1
Jaroonvesama, N1
Charoenlarp, K1
Zubair, M1
Karim, S1
Hussain, S1
Rüegg, UT2
Hof, RP3
Rab, SM1
Mirza, MA1
Khan, MH1
Ahmed, M1
Cabral, EI1
Namin, EP1
Calleja, HB1
Porciuncula, CI1
Divinagracia, RA1
Anastacio, RV1
Schmitz, A1
Andrén, L2
Svensson, A3
Sievert, A1
Aurell, M3
Lijnen, P2
Hespel, P2
Tan, WP1
Devos, P1
Shepherd, AM1
Davidov, M1
Hamilton, J1
Schnaper, H1
Velasquez, M1
Brockway, B1
Gonasun, L2
Frithz, G1
Aström, B1
Tollin, C1
Himanen, P1
Sundstedt, CD3
Wilmoth, SK1
Enevold, GL1
Strickland, HL1
Borhani, NA1
Rupoli, L1
Fruscio, M1
Gradnik, R1
Chianca, R1
Underwood, SM1
Feneck, RO1
Davies, SW1
Walesby, RK1
Lunnon, MW1
Keller, A1
Waite, R1
Nelson, EB2
Velasquez, MT1
Gonasun, LM3
de Almeida, JB1
Amorim, MP1
Cezaretti, ML1
Moerman, E1
Bouvé, J1
Clement, D1
Degraef, R1
Van Thillo, J1
Pool, JL1
Taylor, AA1
Salzmann, R1
Siegl, H1
Huchet, AM1
Gerard, P1
Narcisse, G1
Thys-Jacobs, S1
Kumar, R1
Davidson, WD1
Grayson, M1
Harris, C1
Walker, D1
Itskovitz, H1
Swartz, SL1
Mohanty, PK1
Goodman, RP1
Kirkendal, WM1
Kontos, HA1
Wright, JT1
Kirkendall, W1
Schaefer, EJ1
Chin, B1
Schoenfeld, BH1
Lieberman, S1
Ryan, JR1
Faraday, S1
David-Dufilho, M1
Jie, K1
van Brummelen, P1
Vermey, P1
Timmermans, PB1
van Zwieten, PA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825]Phase 468 participants (Anticipated)Interventional2018-11-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

27 reviews available for isradipine and Blood Pressure, High

ArticleYear
A review of calcium channel antagonists in the treatment of pediatric hypertension.
    Paediatric drugs, 2006, Volume: 8, Issue:6

    Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipi

2006
Partial compliance: implications for clinical practice.
    Journal of cardiovascular pharmacology, 1993, Volume: 22 Suppl A

    Topics: Humans; Hypertension; Isradipine; Patient Compliance

1993
Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine.
    Journal of clinical pharmacology, 1994, Volume: 34, Issue:12

    Topics: Calcium Channel Blockers; Diabetes Complications; Glomerular Filtration Rate; Hemodynamics; Humans;

1994
Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.
    Drugs, 1995, Volume: 49, Issue:4

    Topics: Cardiac Surgical Procedures; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination;

1995
Antihypertensive therapy with isradipine in patients with special safety concerns.
    Angiology, 1994, Volume: 45, Issue:12

    Topics: Blood Pressure; Clinical Trials as Topic; Drug Interactions; Heart; Hemodynamics; Humans; Hypertensi

1994
Role of isradipine and other antihypertensive agents in the treatment of peri- and postoperative hypertension.
    Acta anaesthesiologica Scandinavica. Supplementum, 1993, Volume: 99

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Humans; Hyperte

1993
Cardiac effects of isradipine in patients with hypertension.
    American journal of hypertension, 1993, Volume: 6, Issue:7 Pt 2

    Topics: Coronary Artery Bypass; Heart; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertrophy, Left

1993
Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
    Clinical pharmacy, 1993, Volume: 12, Issue:4

    Topics: Angina Pectoris; Animals; Drug Interactions; Felodipine; Heart Failure; Hemodynamics; Humans; Hypert

1993
Isradipine: a profile in essential hypertension.
    Acta anaesthesiologica Scandinavica. Supplementum, 1993, Volume: 99

    Topics: Animals; Captopril; Drug Therapy, Combination; Humans; Hypertension; Isradipine; Pindolol; Quality o

1993
[Metabolic tolerance of isradipine. Evaluation after three months of therapy].
    La Clinica terapeutica, 1995, Volume: 146, Issue:11

    Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Coronary Artery Disease;

1995
Calcium antagonists in the treatment of hypertension: special clinical considerations.
    Current opinion in nephrology and hypertension, 1996, Volume: 5, Issue:5

    Topics: Angina Pectoris; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents;

1996
Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis.
    Journal of human hypertension, 1997, Volume: 11, Issue:11

    Topics: Antihypertensive Agents; Female; Humans; Hypertension; Isradipine; Male; Middle Aged; Randomized Con

1997
Calcium antagonists and cardiovascular risk in diabetes. A review of the evidence.
    Diabetes care, 1999, Volume: 22, Issue:7

    Topics: Calcium Channel Blockers; Cardiovascular Diseases; Diabetic Angiopathies; Humans; Hypertension; Isra

1999
Isradipine--another calcium-channel blocker for the treatment of hypertension and angina.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:6

    Topics: Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Dihydropyridi

1992
Isradipine: overall clinical experience in hypertension in the United States.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Calcium Channel Blockers; Hemodynamics; Humans; Hypertension; Isradipine; Pyridines; United States

1990
Isradipine: overall clinical experience in hypertension in the United States.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug;

1991
The place of isradipine in the treatment of hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Antihypertensive Agents; Biological Availability; Humans; Hypertension; Isradipine; Pyridines

1991
Isradipine.
    Journal of clinical pharmacy and therapeutics, 1991, Volume: 16, Issue:2

    Topics: Angina Pectoris; Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Human

1991
New drugs for hypertension--variations on old themes.
    Drug and therapeutics bulletin, 1991, Mar-18, Volume: 29, Issue:6

    Topics: Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Doxazosin; Human

1991
Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension; Isra

1990
Review of the international literature on isradipine in hypertension (Lomir/Dynacirc).
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Female; Humans; Hypert

1990
Isradipine in hypertension.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Antihypertensive Agents; Humans; Hypertension; Isradipine; Pyridines

1990
Natriuretic effects of calcium antagonists. Clinical implications.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Animals; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension; Isradipine; Natriuresis; Pyri

1990
Pharmacology of the calcium antagonist isradipine.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Muscle

1990
From channels to cats: an overview of isradipine pharmacology.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels; Hemodynamics; Hyperten

1990
Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Heart; Hemodynamics;

1989
Selective effects of PN 200-110 (isradipine) on the peripheral circulation and the heart.
    The American journal of cardiology, 1987, Jan-30, Volume: 59, Issue:3

    Topics: Animals; Blood Circulation; Calcium Channel Blockers; Heart; Humans; Hypertension; Isradipine; Muscl

1987

Trials

230 trials available for isradipine and Blood Pressure, High

ArticleYear
Isradipine treatment of hypertension in children: a single-center experience.
    Pediatric nephrology (Berlin, Germany), 2002, Volume: 17, Issue:9

    Topics: Adolescent; Blood Pressure; Calcium Channel Blockers; Child; Child, Preschool; Humans; Hypertension;

2002
Glycemia in newborns of hypertensive mothers according to maternal treatment.
    Revista do Hospital das Clinicas, 2004, Volume: 59, Issue:5

    Topics: Antihypertensive Agents; Apgar Score; Atenolol; Blood Glucose; Epidemiologic Methods; Female; Fetal

2004
Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study.
    Journal of clinical hypertension (Greenwich, Conn.), 2005, Volume: 7, Issue:4 Suppl 1

    Topics: Amlodipine; Analysis of Variance; Blood Pressure Determination; Calcium Channel Blockers; Delayed-Ac

2005
Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies.
    American journal of hypertension, 2005, Volume: 18, Issue:6

    Topics: Adult; Amphetamine-Related Disorders; Blood Pressure; Calcium Channel Blockers; Cocaine; Cocaine-Rel

2005
Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril.
    Blood pressure, 1995, Volume: 4, Issue:4

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Drug Therapy, Co

1995
Evaluation of antihypertensive effects of once-a-day isradipine and fosinopril: a double-blind crossover study by means of ambulatory blood pressure monitoring.
    Clinical cardiology, 1995, Volume: 18, Issue:7

    Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents

1995
Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study.
    American journal of obstetrics and gynecology, 1995, Volume: 173, Issue:3 Pt 1

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Hear

1995
The efficacy of isradipine in uncontrolled hypertension in Ethiopian patients.
    Ethiopian medical journal, 1995, Volume: 33, Issue:2

    Topics: Adult; Blood Pressure; Diuretics; Drug Therapy, Combination; Ethiopia; Female; Humans; Hypertension;

1995
Sustained blood pressure control with controlled-release isradipine (isradipine-CR).
    Journal of clinical pharmacology, 1995, Volume: 35, Issue:3

    Topics: Age Factors; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Female; Heart R

1995
A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension.
    Journal of clinical pharmacology, 1995, Volume: 35, Issue:5

    Topics: Adolescent; Adult; Blood Pressure; Double-Blind Method; Enalapril; Female; Humans; Hypertension; Isr

1995
Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial.
    Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Comb

1993
Does isradipine modified release 5 mg once daily reduce blood pressure for 24 hours?
    Journal of cardiovascular pharmacology, 1993, Volume: 22, Issue:2

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Administration Schedule;

1993
Effect of isradipine in black patients with very severe hypertension. 24-hour ambulatory blood pressure monitoring and echocardiographic evaluation.
    American journal of hypertension, 1994, Volume: 7, Issue:12

    Topics: Adult; Aged; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Delayed-Action Pre

1994
Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree?
    Journal of cardiovascular pharmacology, 1995, Volume: 25, Issue:1

    Topics: Adult; Aged; Atenolol; beta-Thromboglobulin; Blood Platelets; Blood Pressure; Cross-Over Studies; Do

1995
Sustained blood pressure control with controlled-release isradipine.
    American journal of hypertension, 1995, Volume: 8, Issue:1

    Topics: Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Hypertension; Isra

1995
At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.
    British journal of clinical pharmacology, 1994, Volume: 38, Issue:4

    Topics: Adult; Aged; Amlodipine; Ankle; Belgium; Blood Pressure; Delayed-Action Preparations; Double-Blind M

1994
[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina].
    Arzneimittel-Forschung, 1994, Volume: 44, Issue:12

    Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Coronary Angiography; Coronary Circulation; Echocar

1994
One year experience of elderly hypertensive patients with isradipine therapy.
    Journal of human hypertension, 1994, Volume: 8, Issue:12

    Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide

1994
Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril.
    International journal of clinical pharmacology and therapeutics, 1994, Volume: 32, Issue:6

    Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Echocardiography, Doppler; Enalapril;

1994
Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension.
    American journal of hypertension, 1994, Volume: 7, Issue:7 Pt 2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Delayed-Action Preparations; Double-

1994
Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension.
    American journal of hypertension, 1994, Volume: 7, Issue:7 Pt 2

    Topics: Adult; Aspirin; Blood Platelets; Blood Pressure; Circadian Rhythm; Dihydropyridines; Double-Blind Me

1994
Hungarian Isradipine Study (HIS): long-term (3-year) effects on blood pressure and plasma lipids.
    American journal of hypertension, 1994, Volume: 7, Issue:7 Pt 2

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Dru

1994
Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients.
    American journal of hypertension, 1994, Volume: 7, Issue:7 Pt 2

    Topics: Adolescent; Adult; Aged; Aging; Blood Pressure; Diastole; Dose-Response Relationship, Drug; Female;

1994
Normalization of resistance artery structure and left ventricular morphology with a perindopril-based regimen.
    The Canadian journal of cardiology, 1994, Volume: 10 Suppl D

    Topics: Antihypertensive Agents; Arteries; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left

1994
Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison of intravenous isradipine and sodium nitroprusside.
    Circulation, 1994, Volume: 90, Issue:5 Pt 2

    Topics: Coronary Artery Bypass; Double-Blind Method; Female; Hemodynamics; Humans; Hypertension; Infusions,

1994
[Lomir for the treatment of patients with essential hypertension and for the rehabilitation of patients with a history of cerebral circulatory disorder].
    Terapevticheskii arkhiv, 1994, Volume: 66, Issue:4

    Topics: Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Chronic Disease; Circadian Rhythm; Fema

1994
Effects of antihypertensive medications on quality of life in elderly hypertensive women.
    American journal of hypertension, 1994, Volume: 7, Issue:4 Pt 1

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Ena

1994
Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients.
    Pharmacology & toxicology, 1993, Volume: 73, Issue:5

    Topics: Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Hyper

1993
[A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension].
    Arquivos brasileiros de cardiologia, 1993, Volume: 61, Issue:5

    Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypertension; Isradipine;

1993
A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension.
    Blood pressure, 1993, Volume: 2, Issue:4

    Topics: Adult; Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood P

1993
[Vasoselective, substance-specific actions of isradipine on the great arteries of hypertensives in comparison to metoprolol].
    Arzneimittel-Forschung, 1994, Volume: 44, Issue:3

    Topics: Adult; Aged; Arteries; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension

1994
Twenty-four hour profile of the anti-hypertensive action of isradipine in essential hypertension.
    Blood pressure, 1993, Volume: 2, Issue:1

    Topics: Adult; Aged; Blood Pressure; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Is

1993
MIDAS: rationale, design and descriptive data of trial patients. The MIDAS Research Group.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Aged; Arteriosclerosis; Carotid Arteries; Double-Blind Method; Female; Humans; Hydrochlorothi

1994
Does the combination of ACE inhibitor and calcium antagonist control hypertension and improve quality of life? The LOMIR-MCT-IL study experience.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cap

1994
Effect of isradipine on cyclosporin A-related hypertension.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Blood Pressure; Cyclosporine; Double-Blind Method; Humans; Hypertension; Isradipine; Kidney Transpla

1994
Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Aspirin; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Dihydro

1994
Isradipine increases platelet--low-density lipoprotein binding: evidence from ex-vivo studies in humans.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Aged; Blood Platelets; Female; Hemodynamics; Humans; Hypercholesterolemia; Hypertension; Isra

1994
A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group.
    Blood pressure, 1993, Volume: 2, Issue:3

    Topics: Adolescent; Adult; Aged; Ankle; Blood Pressure; Double-Blind Method; Drug Tolerance; Edema; Enalapri

1993
Response of ambulatory blood pressure to antihypertensive therapy guided by clinic pressure.
    American journal of hypertension, 1993, Volume: 6, Issue:8

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Drug Therapy, Combination;

1993
[Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo].
    Arzneimittel-Forschung, 1993, Volume: 43, Issue:9

    Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Delayed-Action Preparations

1993
Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women.
    The American journal of medicine, 1994, Volume: 96, Issue:1

    Topics: Aged; Atenolol; Blood Pressure; Double-Blind Method; Enalapril; Female; Humans; Hydrochlorothiazide;

1994
[Circadian antihypertensive action and tolerability of a sustained-release form of isradipine in an intra-individual comparison with nitrendipine].
    Arzneimittel-Forschung, 1993, Volume: 43, Issue:5

    Topics: Adolescent; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Delayed-Action

1993
Intrinsic effect of antihypertensive treatment with isradipine and metoprolol on large artery geometric and elastic properties.
    Clinical pharmacology and therapeutics, 1993, Volume: 54, Issue:1

    Topics: Adult; Aged; Blood Pressure; Brachial Artery; Compliance; Double-Blind Method; Female; Heart Rate; H

1993
Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy.
    The American journal of cardiology, 1993, Sep-01, Volume: 72, Issue:7

    Topics: Cardiovascular System; Exercise Test; Female; Fosinopril; Hemodynamics; Humans; Hypertension; Isradi

1993
Antihypertensive medication-taking. Investigation of a simple regimen.
    American journal of hypertension, 1993, Volume: 6, Issue:7 Pt 1

    Topics: Adult; Clinical Protocols; Double-Blind Method; Drug Evaluation; Female; Humans; Hypertension; Israd

1993
Obesity as a determinant for response to antihypertensive treatment.
    BMJ (Clinical research ed.), 1993, Aug-28, Volume: 307, Issue:6903

    Topics: Blood Pressure; Body Mass Index; Double-Blind Method; Humans; Hypertension; Isradipine; Male; Metopr

1993
Carotid plaque associations among hypertensive patients.
    Archives of internal medicine, 1993, Feb-22, Volume: 153, Issue:4

    Topics: Aged; Arteriosclerosis; Carotid Stenosis; Female; Georgia; Humans; Hydrochlorothiazide; Hypertension

1993
Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study.
    European journal of clinical pharmacology, 1993, Volume: 44, Issue:1

    Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Human

1993
Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring.
    British journal of clinical pharmacology, 1993, Volume: 35, Issue:1

    Topics: Adult; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Female; H

1993
Effects of isradipine and nifedipine retard in hypertensive patients with type II diabetes mellitus.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female;

1993
Antihypertensive efficacy, safety, and tolerability of isradipine in hypertensive patients with diabetes.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy

1993
Antihypertensive effect of the calcium antagonist isradipine and lipid profile.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aged; Blood Pressure; Cholesterol; Humans; Hyperlipidemias; Hypertension; Isradipine; Linear

1993
Transplacental passage of isradipine in the treatment of pregnancy-induced hypertension.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Amniotic Fluid; Delayed-Action Preparations; Female; Fetal Blood; Humans; Hypertension; Isradipine;

1993
Parenteral isradipine reduces blood pressure in hypertensive crisis.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Acute Disease; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypertension; Infusions, In

1993
Calcium antagonists and atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aged; Arteriosclerosis; Carotid Arteries; Double-Blind Method; Female; Humans; Hydrochlorothi

1993
Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS).
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure Determination; Drug Therapy, C

1993
A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Ankle; Double-Blind Method; Drug Therapy, Combination; Edema; Enalapril; Felodipine; Female;

1993
Efficacy, safety, and tolerability of isradipine in hypertension as used in general practice in a developing country (Pakistan).
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Developing Countries; Family Practice; Female; Humans; Hypertension; Isradipine; Male; Middle

1993
A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Captopril; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Isradipine;

1993
Reexamining the quality of life of hypertensive patients. A new self-structured measure.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Analysis of Variance; Factor Analysis, Statistical; Humans; Hypertension; Isradipine; Male; M

1993
Isradipine: a slow-release formulation given once daily controls blood pressure for 24 h.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Fe

1993
Efficacy of slow-release oral isradipine in moderate-to-severe hypertension with add-on spirapril.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Delayed-Action Preparations; Drug Th

1993
A comparative study of isradipine SRO and enalapril in black patients with mild-to-moderate hypertension.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Black People; Delayed-Action Preparations; Double-Blind Method; Enalapril; Humans; Hypertensi

1993
Regression of left ventricular hypertrophy with isradipine antihypertensive therapy.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Aged; Echocardiography; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricula

1993
Reversal of left ventricular hypertrophy with isradipine induces diminution of cardiac arrhythmias.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aged; Arrhythmias, Cardiac; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left

1993
Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Echocardiography, Doppler; Female; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left

1993
Effect of short-term antihypertensive therapy on left ventricular wall tension. A double-blind comparison of isradipine and nifedipine.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Cardiac Volume; Double-Blind Method; Female; Heart Ventricles; Humans; Hypertension; Isradipine; Mal

1993
Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Aged; Atenolol; Blood Pressure; Double-Blind Method; Exercise Tolerance; Heart Rate; Heart Ventricle

1993
Treatment of hypertension with calcium antagonists and aspirin. Effects on 24-h platelet activity.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aspirin; Circadian Rhythm; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hy

1993
Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery.
    Acta anaesthesiologica Scandinavica. Supplementum, 1993, Volume: 99

    Topics: Adolescent; Adult; Aged; Coronary Artery Bypass; Female; Hemodynamics; Humans; Hypertension; Infusio

1993
Dose titration study of isradipine in Chinese patients with mild to moderate essential hypertension.
    Cardiovascular drugs and therapy, 1993, Volume: 7, Issue:1

    Topics: Adult; Blood Pressure; China; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hyperten

1993
Metabolic effects of isradipine in non-insulin-dependent diabetes mellitus (NIDDM) hypertensive patients.
    Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:3

    Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Delayed-Act

1995
Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine.
    Journal of cardiovascular pharmacology, 1995, Volume: 26, Issue:5

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Ch

1995
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes.
    Journal of clinical pharmacology, 1996, Volume: 36, Issue:3

    Topics: Adult; Albuminuria; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, S

1996
[Metabolic tolerance of isradipine. Evaluation after three months of therapy].
    La Clinica terapeutica, 1995, Volume: 146, Issue:11

    Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Disorders; Coronary Artery Disease;

1995
[Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study].
    Arzneimittel-Forschung, 1996, Volume: 46, Issue:6

    Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Fema

1996
Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries.
    Hypertension (Dallas, Tex. : 1979), 1996, Volume: 28, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Blood Pressure; Drug Co

1996
Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.
    Cardiovascular drugs and therapy, 1996, Volume: 10, Issue:2

    Topics: Antihypertensive Agents; beta-Thromboglobulin; Blood Pressure; Calcium Channel Blockers; Delayed-Act

1996
Analysis of blood pressure rhythms for drug efficacy evaluation.
    Annals of the New York Academy of Sciences, 1996, Aug-15, Volume: 783

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Chronotherapy; F

1996
Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study.
    Journal of human hypertension, 1996, Volume: 10, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents

1996
Treatment of non-insulin-dependent diabetic hypertensive patients with Ca2+ channel blockers is associated with increased platelet sensitivity to insulin.
    American journal of hypertension, 1995, Volume: 8, Issue:12 Pt 1

    Topics: Angiotensin II; Antihypertensive Agents; Blood Platelets; Blood Pressure; Calcium; Calcium Channel B

1995
Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients.
    American journal of hypertension, 1997, Volume: 10, Issue:1

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Isradipine; Male; Midd

1997
Effect of calcium channel blockade on skin blood flow in diabetic hypertension: a comparison of isradipine and atenolol.
    Angiology, 1997, Volume: 48, Issue:3

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers

1997
Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study.
    Transplantation, 1997, Apr-15, Volume: 63, Issue:7

    Topics: Adult; Antihypertensive Agents; Bone Marrow Transplantation; Cyclosporine; Female; Humans; Hypertens

1997
Isradipine therapy in hypertensive pediatric patients.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:6

    Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Dosage Forms; Humans; Hypertension; In

1997
Effect of isradipine on in-vivo platelet function.
    Thrombosis research, 1997, Jun-01, Volume: 86, Issue:5

    Topics: Adult; Aged; Arteriosclerosis; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Cell Survi

1997
Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine.
    Journal of periodontology, 1997, Volume: 68, Issue:7

    Topics: Adult; Aged; Antihypertensive Agents; Biopsy; Calcium Channel Blockers; Dental Plaque Index; Evaluat

1997
Salt and blood pressure responses to calcium antagonism in hypertensive patients.
    Hypertension (Dallas, Tex. : 1979), 1997, Volume: 30, Issue:3 Pt 1

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies;

1997
Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity.
    Angiology, 1997, Volume: 48, Issue:11

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertensi

1997
Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group.
    Journal of the American College of Cardiology, 1997, Volume: 30, Issue:7

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Double-Blind Method; E

1997
Comparison of isradipine and enalapril effects on regional carotid circulation in patients with hypertension with unilateral internal carotid artery stenosis.
    Journal of cardiovascular pharmacology, 1997, Volume: 30, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B

1997
Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy.
    Journal of hypertension, 1997, Volume: 15, Issue:12 Pt 1

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Echocardiography; Hear

1997
Vasoconstriction during acute hypervolemic hemodilution in hypertensive patients is not prevented by calcium blockade.
    Angiology, 1998, Volume: 49, Issue:1

    Topics: Antihypertensive Agents; Blood Pressure; Blood Viscosity; Blood Volume; Calcium Channel Blockers; Ca

1998
Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects.
    Journal of human hypertension, 1997, Volume: 11, Issue:12

    Topics: Adrenergic beta-Antagonists; Adult; Atenolol; beta-Thromboglobulin; Blood Platelets; Blood Pressure;

1997
Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension.
    Cardiovascular drugs and therapy, 1997, Volume: 11, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B

1997
Increased urinary cGMP and decreased albumin excretion with isradipine treatment in essential hypertension.
    Cardiovascular drugs and therapy, 1997, Volume: 11, Issue:5

    Topics: Adult; Albumins; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cyclic GMP; Doub

1997
Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens.
    American journal of hypertension, 1998, Volume: 11, Issue:3 Pt 1

    Topics: Adult; Amiloride; Antihypertensive Agents; Arteries; Buttocks; Calcium Channel Blockers; Diuretics;

1998
Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing.
    American journal of hypertension, 1998, Volume: 11, Issue:3 Pt 1

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure;

1998
Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.
    Hypertension (Dallas, Tex. : 1979), 1998, Volume: 31, Issue:5

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Ch

1998
Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity.
    American journal of hypertension, 1998, Volume: 11, Issue:6 Pt 1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Press

1998
Isradipine in prediabetic hypertensive subjects.
    Diabetes care, 1998, Volume: 21, Issue:12

    Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cardiovascular Dis

1998
Isradipine lowers human arterial low density lipoprotein retention in vivo.
    Prostaglandins, leukotrienes, and essential fatty acids, 1998, Volume: 59, Issue:5

    Topics: Adult; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Carotid Arteries

1998
Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.
    Scandinavian journal of urology and nephrology, 1999, Volume: 33, Issue:1

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug

1999
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.
    Lancet (London, England), 1997, Oct-11, Volume: 350, Issue:9084

    Topics: Arteriosclerosis; Blood Glucose; Calcium Channel Blockers; Cardiovascular Diseases; Carotid Artery D

1997
The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability.
    European journal of clinical pharmacology, 1999, Volume: 55, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten

1999
Hypertension after liver transplantation: a predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations.
    American journal of hypertension, 2000, Volume: 13, Issue:3

    Topics: Adult; Blood Circulation; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Female; Flushi

2000
Effects of enalapril and isradipine alone and in combination on blood pressure, renal function and echocardiographic parameters in mild hypertension.
    International journal of cardiology, 2000, Jun-12, Volume: 74, Issue:1

    Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind Meth

2000
Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators.
    American journal of hypertension, 2000, Volume: 13, Issue:11

    Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Dou

2000
[Comparison of nicardipine and isradipine in hypertension following coronary artery bypass graft].
    Annales francaises d'anesthesie et de reanimation, 2002, Volume: 21, Issue:3

    Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Coronary Artery Bypass; Female; Hemodynamic

2002
Effects of antihypertensive therapy on hemorheological profiles in female hypertensive patients with initially low or high whole blood viscosity.
    Clinical hemorheology and microcirculation, 2002, Volume: 26, Issue:2

    Topics: Antihypertensive Agents; Blood Pressure; Blood Viscosity; Enalapril; Erythrocytes; Female; Fibrinoge

2002
Efficacy, tolerability and safety of isradipine (Lomir) in the treatment of mild to moderate Tanzanian hypertensives.
    East African medical journal, 1992, Volume: 69, Issue:12

    Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Isradipine; Male; Middle Aged; Seve

1992
Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension.
    The American journal of cardiology, 1992, May-01, Volume: 69, Issue:14

    Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calc

1992
[Multicenter study of isradipine in the treatment of hypertension].
    Vnitrni lekarstvi, 1992, Volume: 38, Issue:4

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Therapy

1992
MIS (Multicentric Isradipine Study of antihypertensive therapy).
    Cor et vasa, 1992, Volume: 34, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug The

1992
Effect of isradipine on cardiopulmonary baroreflex function, regional blood flow, and vascular responsiveness in hypertensive patients.
    Journal of cardiovascular pharmacology, 1992, Volume: 19, Issue:2

    Topics: Adult; Angiotensin II; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyr

1992
MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. MIDAS Research Group.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Antihypertensive Agents; Arteriosclerosis; Dihydropyridines; Double-Blind Method; Female; Humans; Hy

1992
Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance study.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Calcium Channel Blockers; Dihydropyridines; Drug Administration Schedule; Drug Tolerance; Humans; Hy

1992
Long-term (2-year) isradipine data in the treatment of mild-to-moderate hypertension.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Calcium Channel Blockers; Dihydropyridines; Drug Administration Schedule; Humans; Hypertension; Isra

1992
Isradipine in the treatment of mild-to-moderate hypertension in Portugal.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Adolescent; Adult; Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Dihydropyridines; Fe

1992
Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Adult; Age Factors; Aged; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Tolerance

1992
Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Isradipine

1992
Pharmacological modulation of stress-induced cardiovascular hyperreactivity in essential hypertension.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Hemodynamics; Humans; Hypertension;

1992
Isradipine in the treatment of hypertensive crisis in ambulatory patients.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Administration, Sublingual; Ambulatory Care; Blood Pressure; Calcium Channel Blockers; Dihydropyridi

1992
Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Adolescent; Adult; Aged; Calcium Channel Blockers; Cardiomegaly; Dihydropyridines; Drug Therapy, Com

1992
Hemodynamic effects of isradipine and nifedipine in chronic sustained hypertension.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Aged; Calcium Channel Blockers; Dihydropyridines; Hemodynamics; Humans; Hypertension; Infusions, Int

1992
Effects of isradipine on hypertension and renal hemodynamics.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Adult; Calcium Channel Blockers; Dihydropyridines; Female; Hemodynamics; Humans; Hypertension; Israd

1992
Long-term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Administration, Oral; Adult; Aged; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension;

1992
Effect of isradipine on responses to standardized physical stress tests in hypertension of pregnancy.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Exercise Test; Female; Heart Rate; Human

1992
Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH).
    Journal of cardiovascular pharmacology, 1992, Volume: 20, Issue:2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Blind Method; Drug Th

1992
Isradipine for the treatment of hypertension following coronary artery bypass graft surgery: a randomized trial versus sodium nitroprusside.
    European journal of anaesthesiology, 1992, Volume: 9, Issue:4

    Topics: Adult; Aged; Calcium Channel Blockers; Coronary Artery Bypass; Dihydropyridines; Female; Humans; Hyp

1992
Clinical studies on isradipine in the management of adult hypertensive patients at Moi University Teaching Hospital, Eldoret, Kenya.
    East African medical journal, 1992, Volume: 69, Issue:2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Female; Heart Rate; Hospitals, Uni

1992
Effects of calcium channel blockers on cardiovascular responses to smoking in normotensive and hypertensive smokers.
    International journal of clinical pharmacology research, 1992, Volume: 12, Issue:2

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Heart Rate; Hemodynami

1992
Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension.
    The American journal of cardiology, 1992, Nov-15, Volume: 70, Issue:15

    Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitors; Double-Blin

1992
Serum lipoprotein profile under different antihypertensive therapy.
    International journal of clinical pharmacology research, 1992, Volume: 12, Issue:3

    Topics: Adult; Antihypertensive Agents; Benzazepines; Blood Pressure; Cholesterol; Cholesterol, HDL; Drug Co

1992
Flow resistance and its components in hypertensive men treated with the calcium antagonist isradipine.
    European journal of clinical pharmacology, 1992, Volume: 43, Issue:5

    Topics: Adult; Aged; Arteries; Blood Pressure; Compliance; Hemodynamics; Humans; Hypertension; Isradipine; M

1992
Antihypertensive and hemodynamic effects of calcium channel blockade with isradipine after acute exercise.
    American journal of hypertension, 1992, Volume: 5, Issue:2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Dihydropyr

1992
Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria.
    Journal of internal medicine, 1992, Volume: 231, Issue:3

    Topics: Albuminuria; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Double-Blind Metho

1992
A comparison of the safety of therapeutically equivalent doses of isradipine and diltiazem for treatment of essential hypertension.
    American journal of hypertension, 1992, Volume: 5, Issue:3

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Diltiazem; Dose-Response Rel

1992
Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy.
    American journal of hypertension, 1992, Volume: 5, Issue:5 Pt 1

    Topics: Antihypertensive Agents; Dihydropyridines; Double-Blind Method; Humans; Hypertension; Isradipine; Ki

1992
A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects.
    The British journal of clinical practice, 1991,Autumn, Volume: 45, Issue:3

    Topics: Adult; Aged; Antihypertensive Agents; Cough; Dihydropyridines; Drug Therapy, Combination; Enalapril;

1991
Effect of isradipine on platelet aggregation and oxygen free radicals in hypertension.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1991, Volume: 9, Issue:6

    Topics: Adult; Aged; Antihypertensive Agents; Dihydropyridines; Female; Free Radicals; Humans; Hydrogen Pero

1991
Antihypertensive effect of isradipine on blood pressure at rest and during exercise.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response

1991
Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Heart Rate; Humans; Hypertens

1990
Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Heart Rate; Humans; Hypertens

1990
Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dose-Response Relat

1990
Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Ankle; Blood Pressure; Body Weight; Brachial Artery; Calcium Channel Blockers; Double-Blind Method;

1990
Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diet; Double-Bli

1990
Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; H

1991
The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Aged; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Dihydropyridines; Double-

1991
Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Captopril; Dihydropy

1991
Does antihypertensive therapy affect the natural protection against thrombosis?
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Fi

1991
First clinical experience with isradipine in the treatment of hypertension in Portugal.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Double-B

1991
Sleep disturbances in hypertension: a double-blind study between isradipine and metoprolol.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Humans; Hypertension; Isradi

1991
The antihypertensive action of isradipine in mild essential hypertension.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Blind Method; Humans; Hyper

1991
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Doubl

1991
Assessment of electrocardiographic ischemia in hypertensive patients treated with isradipine or placebo.
    Journal of clinical pharmacology, 1991, Volume: 31, Issue:3

    Topics: Adult; Aged; Antihypertensive Agents; Coronary Disease; Electrocardiography; Female; Humans; Hyperte

1991
MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Carotid Arteries; Diuretics;

1991
Multicenter evaluation of efficacy, tolerability and safety of a new first-line antihypertensive drug, isradipine, in a Latin-American population.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Cohort Studies; Colombia; Dose-Re

1991
Isradipine twice daily lowers blood pressure over 24 H.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Dose-Response Relationship,

1991
Isradipine in the treatment of hypertension. Some additional effects observed during a one-year study.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Echocardiography; Exercise; Femal

1991
Time course of the blood pressure response to oral isradipine in uncomplicated mild-to-moderate essential hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Heart Rate; Humans; Hypertensi

1991
Antihypertensive effects of isradipine and captopril as monotherapy or in combination.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc

1991
A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind

1991
Effect of isradipine on 24-h blood pressure profile demonstrated by repeated monitoring.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Circadian Rhyth

1991
Twenty-four-hour blood pressure control with isradipine in mild essential hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Doub

1991
Low-dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Dose-Respons

1991
Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Female; Fibrinolysis; Humans

1991
Effect of isradipine on factors affecting blood viscosity.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Viscosity; Calcium Channel Blockers; Dou

1991
Platelet-activating effect of low-density lipoprotein and its reversal by isradipine.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Cre

1991
Effects of isradipine on platelet function in hypertension at rest and during exercise.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Antihypertensive Agents; beta-Thromboglobulin;

1991
Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Apolipoproteins; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Bli

1991
Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Electrocardiography; Humans; Hypertension; I

1991
Acute antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Creatine; Glomerular Filtration Rate;

1991
Effects of isradipine on peripheral hemodynamic reflex responses in mild-to-moderate essential hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Cold Temperature; Double-Blind Method; Exercise; Fem

1991
Effect of isradipine and atenolol on lung function in patients with mild essential hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Aged; Airway Resistance; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Female;

1991
Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Female; Fetus; Hea

1991
Management of perioperative hypertension using intravenous isradipine.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antihypertensive Agents; Double-Bli

1991
Isradipine, a calcium antagonist, in the control of hypertension following coronary artery-bypass surgery.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Calcium Channel Blockers; Cardiac Output; Coronary Artery Bypass; Heart Rate; Humans; Hypertension;

1991
A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients.
    Journal of human hypertension, 1991, Volume: 5, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparation

1991
Isradipine.
    Journal of clinical pharmacy and therapeutics, 1991, Volume: 16, Issue:2

    Topics: Angina Pectoris; Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Human

1991
Isradipine in the treatment of mild to moderate essential hypertension.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1991, Oct-05, Volume: 80, Issue:7

    Topics: Antihypertensive Agents; Dihydropyridines; Humans; Hypertension; Isradipine; Male

1991
The use of calcium antagonists to treat intra-operative hypertension--evaluation of efficacy and safety of a new dihydropyridine derivative, intravenous isradipine, during abdominal surgery.
    European journal of anaesthesiology, 1991, Volume: 8, Issue:5

    Topics: Abdomen; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Double

1991
[The hemodynamic effects of isradipine and nifedipine in hypertension].
    Arzneimittel-Forschung, 1991, Volume: 41, Issue:9

    Topics: Adult; Blood Pressure; Cardiac Output; Dihydropyridines; Female; Heart; Heart Function Tests; Humans

1991
[Clinical trial with isradipine in the treatment of mild and moderate arterial hypertension].
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 1991, Volume: 10, Issue:12

    Topics: Adult; Aged; Antihypertensive Agents; Dihydropyridines; Female; Humans; Hypertension; Isradipine; Ma

1991
Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Press

1990
The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients.
    American journal of hypertension, 1990, Volume: 3, Issue:1

    Topics: Antihypertensive Agents; Black People; Blood Pressure; Calcium Channel Blockers; Cardiomyopathy, Hyp

1990
Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure.
    The American journal of cardiology, 1990, Feb-15, Volume: 65, Issue:7

    Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Delayed-Action Preparations; Doubl

1990
The pharmokinetics of isradipine in hypertensive subjects.
    European journal of clinical pharmacology, 1990, Volume: 38, Issue:2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chromatography, High Pressure Liquid; Female;

1990
Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension; Isra

1990
Effect of isradipine, a new calcium antagonist on the lipid profile in patients with hypertension.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Antihypertensive Agents; Apolipoproteins; Calcium Channel Blockers; Cholesterol; Double-Blind Method

1990
Review of the international literature on isradipine in hypertension (Lomir/Dynacirc).
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Female; Humans; Hypert

1990
Multicenter comparison of once- and twice-daily isradipine to hydrochlorothiazide for the treatment of hypertension in elderly patients.
    Clinical pharmacology and therapeutics, 1990, Volume: 48, Issue:5

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administ

1990
Placebo-controlled trial of once-a-day isradipine monotherapy in mild to moderately severe hypertension.
    Journal of clinical pharmacology, 1990, Volume: 30, Issue:11

    Topics: Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Female; Heart Rate; Humans; H

1990
Improved compliance measures: applications in an ambulatory hypertensive drug trial.
    Clinical pharmacology and therapeutics, 1990, Volume: 48, Issue:6

    Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Packaging; Enalapril; Humans; Hyp

1990
[Evaluation of the 24-hour effect of a once-daily antihypertensive drug on the diurnal blood pressure profile].
    Schweizerische medizinische Wochenschrift, 1990, Dec-08, Volume: 120, Issue:49

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Female; Humans; Hypertension; Israd

1990
Multicentre isradipine dose-confirmation study in Thai patients with hypertension.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Isradipine; Male; Midd

1990
Isradipine in Asian patients with hypertension.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Isradipine; Male; Middle Aged; Pakista

1990
Double-blind multicentre isradipine dose-confirmation study in Pakistan.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Adult; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension; Isradipine; Male;

1990
Isradipine dose-confirmation study in Filipino patients with mild to moderate hypertension.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Isradipine; Male; Midd

1990
The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hypertension;

1990
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension.
    Journal of cardiovascular pharmacology, 1987, Volume: 10 Suppl 10

    Topics: Adult; Aged; Blood Pressure; Calcium; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, C

1987
Effects of the new calcium entry blocker isradipine (PN 200-110) in essential hypertension.
    Journal of cardiovascular pharmacology, 1989, Volume: 13, Issue:2

    Topics: Blood Pressure; Calcium Channel Blockers; Cations; Clinical Trials as Topic; Double-Blind Method; El

1989
Efficacy and safety of isradipine in hypertension.
    Journal of cardiovascular pharmacology, 1989, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-B

1989
Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension.
    Journal of cardiovascular pharmacology, 1989, Volume: 14, Issue:1

    Topics: Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Humans; Hyp

1989
Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. The British Isradipine Hypertension Group.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic

1989
Improved blood pressure control with isradipine in hypertensive patients treated with pindolol.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method;

1989
A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Isradipine in Hypertension Study Group.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind

1989
Additive effect of isradipine in combination with captopril in hypertensive patients.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Captopril; Double-Blind Method; Drug

1989
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Clinical Trials as Topic

1989
Differential effects of isradipine and atenolol on peripheral hemodynamics and arterial compliance.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Fe

1989
Renal and hemodynamic effects of isradipine in essential hypertension.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Double-Blind Meth

1989
Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients. Dose-response curves of the different effects.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug;

1989
Use of isradipine in hypertension following coronary artery bypass surgery.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Central

1989
Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug;

1989
Multicenter evaluation of the safety and efficacy of isradipine in hypertension. The Italian-Belgian Isradipine Study Group.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adult; Aged; Antihypertensive Agents; Belgium; Blood Pressure; Calcium Channel Blockers; Double-Blin

1989
A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Tolerance; Elec

1989
Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men.
    Journal of hypertension, 1989, Volume: 7, Issue:6

    Topics: Administration, Oral; Ankle; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinical Trials

1989
Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives. A multicenter evaluation.
    Archives of internal medicine, 1989, Volume: 149, Issue:11

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administration Sched

1989
Differential effects of non-specific beta-blockade and calcium antagonism on blood-clotting mechanisms.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adult; Aged; Antihypertensive Agents; Blood Coagulation; Blood Platelets; Calcium Channel Blockers;

1989
Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II.
    European journal of clinical pharmacology, 1989, Volume: 36, Issue:6

    Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Blood Pressure; Calcium Channel Blockers;

1989
Isradipine in essential hypertension: the Belgian General Practitioners' Study.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Adrenergic alpha-Agonists; Adult; Aged; Antihypertensive Agents; Belgium; Blood Pressure; Calcium Ch

1989
Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist.
    Clinical pharmacology and therapeutics, 1986, Volume: 40, Issue:6

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Drug

1986
Antihypertensive effect of a new dihydropyridine calcium antagonist, PN 200-110 (isradipine), combined with pindolol.
    The American journal of cardiology, 1987, Jan-30, Volume: 59, Issue:3

    Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method

1987
Treatment of essential hypertension with PN 200-110 (isradipine).
    The American journal of cardiology, 1987, Jan-30, Volume: 59, Issue:3

    Topics: Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Drug Therap

1987
Evaluation of isradipine (PN 200-110) in mild to moderate hypertension.
    Clinical pharmacology and therapeutics, 1987, Volume: 42, Issue:4

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Drug

1987
The long-term effect of isradipine in pindolol-treated patients.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1987, Volume: 5, Issue:5

    Topics: Aged; Body Weight; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Edema;

1987
Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension. A multicenter study.
    American journal of hypertension, 1988, Volume: 1, Issue:3 Pt 3

    Topics: Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Heart Rate; Humans; Hydrochlorot

1988
Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension.
    The American journal of cardiology, 1988, Nov-15, Volume: 62, Issue:16

    Topics: Adult; Aged; Apolipoproteins; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hydroch

1988
An acute dose-response pharmacodynamic evaluation of orally administered isradipine (PN-200-110) in hypertensive patients.
    Journal of clinical pharmacology, 1988, Volume: 28, Issue:7

    Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug;

1988
Influence of calcium entry blockade on alpha 1- and alpha 2-adrenoceptor mediated vasoconstriction in the forearm of hypertensive patients.
    European journal of clinical pharmacology, 1987, Volume: 32, Issue:2

    Topics: Adult; Azepines; Calcium Channel Blockers; Female; Forearm; Hemodynamics; Humans; Hypertension; Isra

1987

Other Studies

93 other studies available for isradipine and Blood Pressure, High

ArticleYear
Nanostructured lipid carriers of isradipine for effective management of hypertension and isoproterenol induced myocardial infarction.
    Drug delivery and translational research, 2022, Volume: 12, Issue:3

    Topics: Administration, Oral; Animals; Antioxidants; Drug Carriers; Hypertension; Isoproterenol; Isradipine;

2022
Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study.
    Artificial cells, nanomedicine, and biotechnology, 2017, Volume: 45, Issue:1

    Topics: Administration, Cutaneous; Animals; Hypertension; Isradipine; Liposomes; Rats; Rats, Wistar

2017
Isradipine for treatment of acute hypertension in hospitalized children and adolescents.
    Journal of clinical hypertension (Greenwich, Conn.), 2010, Volume: 12, Issue:11

    Topics: Acute Disease; Adolescent; Age Factors; Blood Pressure; Calcium Channel Blockers; Child; Child, Pres

2010
Phenytoin/isradipine interaction causing severe neurologic toxicity.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:9

    Topics: Acidosis; Adult; Anticonvulsants; Antihypertensive Agents; Calcium Channel Blockers; Drug Interactio

2002
[Isradipine-SRO: antihypertensive efficacy, central and peripheral hemodynamic effects in patients with hypertensive disease].
    Kardiologiia, 2003, Volume: 43, Issue:6

    Topics: Adult; Aged; Calcium Channel Blockers; Female; Hemodynamics; Humans; Hypertension; Isradipine; Male;

2003
Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
    Current medical research and opinion, 2006, Volume: 22, Issue:7

    Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Double-Blind Method; Drug Toler

2006
Calcium channel blockers as inhibitors of angiotensin I-converting enzyme.
    Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:6 Pt 2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Blotting

1995
Influence of graded changes in vasomotor tone on the carotid arterial mechanics in live spontaneously hypertensive rats.
    British journal of pharmacology, 1995, Volume: 115, Issue:7

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Carotid Arteries; Hypert

1995
[The compliance of the large elastic arteries after blood pressure-lowering therapy with a calcium antagonist].
    Deutsche medizinische Wochenschrift (1946), 1995, Jun-23, Volume: 120, Issue:25-26

    Topics: Aorta; Aorta, Thoracic; Blood Pressure; Calcium Channel Blockers; Compliance; Female; Humans; Hypert

1995
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 1995, Issue:5

    Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin;

1995
Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
    European journal of pharmacology, 1995, May-04, Volume: 278, Issue:1

    Topics: Alkaloids; Animals; Antihypertensive Agents; Benzylisoquinolines; Binding, Competitive; Blood Pressu

1995
Endothelin modulates dihydropyridine receptor decreased binding in hippocampal slices from normotensive and spontaneously hypertensive rats.
    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 1993, Volume: 11, Issue:3

    Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e

1993
Binding of [3H](+)-PN200-110 to aortic membranes from normotensive and spontaneously hypertensive rats.
    European journal of pharmacology, 1994, Oct-24, Volume: 264, Issue:2

    Topics: Aging; Animals; Aorta, Abdominal; Aorta, Thoracic; Calcium Channels; Disease Models, Animal; Hyperte

1994
Effect of long term isradipine treatment on the morphology of the endothelium in the aorta of spontaneously hypertensive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 1994, Volume: 16, Issue:6

    Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Endothelium, Vascular; Hypertension; Isradipine; Male; M

1994
Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats.
    Journal of hypertension, 1994, Volume: 12, Issue:5

    Topics: Animals; Aorta; Blood Pressure; Hydralazine; Hypertension; Isradipine; Male; Microscopy, Electron; M

1994
Intravenous isradipine in the management of severe hypertension in pregnant and nonpregnant patients. A pilot study.
    American journal of hypertension, 1994, Volume: 7, Issue:7 Pt 2

    Topics: Adolescent; Adult; Black People; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Inj

1994
Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
    Journal of internal medicine, 1994, Volume: 236, Issue:1

    Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Hemoglobin A;

1994
Statistical evaluation of circadian blood pressure rhythm during isradipine long-term therapy.
    European journal of clinical pharmacology, 1994, Volume: 46, Issue:2

    Topics: Blood Pressure; Circadian Rhythm; Female; Fourier Analysis; Humans; Hypertension; Isradipine; Male;

1994
Evaluation of the effectiveness of isradipine SRO in the treatment of hypertensive patients with left ventricular hypertrophy.
    Cardiovascular drugs and therapy, 1994, Volume: 8, Issue:1

    Topics: Aged; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Isradipine; Mal

1994
Update on perioperative hypertension: the place of intravenous isradipine. Proceedings of a workshop. Sonoma, California, October 26, 1991.
    Acta anaesthesiologica Scandinavica. Supplementum, 1993, Volume: 99

    Topics: Animals; Humans; Hypertension; Intraoperative Complications; Isradipine; Postoperative Complications

1993
Influence of isradipine treatment on left ventricular and coronary vascular hypertrophy in spontaneously hypertensive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 1994, Volume: 16, Issue:1

    Topics: Animals; Blood Pressure; Coronary Vessels; Hypertension; Hypertrophy; Hypertrophy, Left Ventricular;

1994
Indication for antihypertensive treatment: superiority of ambulatory vs casual blood pressure measurement.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Aged; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure Determination

1994
Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adolescent; Adult; Black People; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rat

1994
Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Angiography; Arteries; Blood Pressure; Female; Gamma Rays; Humans; Hyperlipoproteinemias; Hyp

1994
Isradipine decreases exercise-induced albuminuria in patients with essential hypertension.
    Renal failure, 1993, Volume: 15, Issue:4

    Topics: Albuminuria; Blood Pressure; Exercise; Exercise Test; Female; Humans; Hypertension; Isradipine; Male

1993
Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients.
    European journal of clinical pharmacology, 1993, Volume: 45, Issue:2

    Topics: Heart Transplantation; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Isradipine; Male;

1993
Effects of sustained-release isradipine on left ventricular anatomy and function in systemic hypertension.
    The American journal of cardiology, 1993, Dec-01, Volume: 72, Issue:17

    Topics: Adult; Delayed-Action Preparations; Echocardiography; Female; Heart Ventricles; Humans; Hypertension

1993
[Chronic diarrhea caused by isradipine].
    Gastroenterologie clinique et biologique, 1993, Volume: 17, Issue:4

    Topics: Chronic Disease; Diarrhea; Female; Humans; Hypertension; Isradipine; Middle Aged

1993
Structural changes in the endothelium of the femoral artery of spontaneously hypertensive rats: sensitivity to isradipine treatment.
    Journal of hypertension, 1993, Volume: 11, Issue:5

    Topics: Animals; Endothelium, Vascular; Femoral Artery; Hypertension; Isradipine; Male; Microscopy, Electron

1993
Antihypertensive effect of isradipine on ambulatory and casual blood pressure.
    American journal of hypertension, 1993, Volume: 6, Issue:3 Pt 2

    Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitors; Humans; Hyperten

1993
[The antihypertensive effect of isradipine and additional pharmacodynamic effects].
    Vnitrni lekarstvi, 1993, Volume: 39, Issue:3

    Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Isradipine; Lipids; Male; Middle Aged; Re

1993
Hypertensive crisis in children.
    Pediatric annals, 1996, Volume: 25, Issue:7

    Topics: Antihypertensive Agents; Emergencies; Enalapril; Humans; Hypertension; Isradipine; Labetalol; Nicard

1996
Effects of isradipine treatment on oxidative stress markers in patients with essential hypertension.
    Journal of human hypertension, 1996, Volume: 10, Issue:8

    Topics: Adult; Humans; Hypertension; Isradipine; Oxidative Stress; Thiobarbituric Acid Reactive Substances

1996
[Isradipine in arterial hypertension in motor vehicle drivers].
    Meditsina truda i promyshlennaia ekologiia, 1996, Issue:8

    Topics: Adult; Antihypertensive Agents; Automobile Driving; Blood Pressure; Calcium Channel Blockers; Humans

1996
Vascular events during antihypertensive treatment.
    The Journal of family practice, 1996, Volume: 43, Issue:6

    Topics: Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Carotid Stenosis; Diuret

1996
[The prolonged-action form of Lomir (isradipine) in the treatment of mild and moderate essential hypertension].
    Terapevticheskii arkhiv, 1996, Volume: 68, Issue:9

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Chronic Disease; Delayed-Action Preparations; Drug E

1996
Hypertensive heart disease: quantitative evaluation of response to therapy with cine MR imaging.
    Academic radiology, 1997, Volume: 4, Issue:9

    Topics: Adult; Analysis of Variance; Antihypertensive Agents; Cardiac Volume; Evaluation Studies as Topic; F

1997
Treatment of hypertensive patients with diabetes.
    Lancet (London, England), 1998, Mar-07, Volume: 351, Issue:9104

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block

1998
[Calcium antagonists and their impact on coronary risk].
    Medicina clinica, 1998, Feb-21, Volume: 110, Issue:6

    Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic;

1998
[Comparative efficacy of and tolerance to prestarium and lomir in long-term treatment of hypertensive subjects].
    Klinicheskaia meditsina, 1998, Volume: 76, Issue:3

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Dos

1998
Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve.
    American journal of hypertension, 1998, Volume: 11, Issue:7

    Topics: Antihypertensive Agents; Arterioles; Bisoprolol; Blood Pressure; Coronary Circulation; Diastole; Dil

1998
Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension.
    Clinical hemorheology and microcirculation, 1998, Volume: 18, Issue:2-3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Viscosity; Calcium Channel Blockers;

1998
[Long-term monotherapy with prestarium, anap and lomir in patients with mild and moderate arterial hypertension: clinical efficacy, hemodynamics and morphofunctional parameters of heart].
    Terapevticheskii arkhiv, 1998, Volume: 70, Issue:9

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Azides; Blood Pressure; Calcium Channel Block

1998
Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients.
    Cardiovascular research, 1999, Volume: 41, Issue:1

    Topics: Acetylcholine; Adult; Analysis of Variance; Calcium Channel Blockers; Case-Control Studies; Dose-Res

1999
Isradipine and insulin sensitivity in hypertensive rats.
    The American journal of physiology, 1999, Volume: 276, Issue:6

    Topics: Animals; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Glucose Clamp T

1999
Initial experience with isradipine for the treatment of hypertension in children.
    Southern medical journal, 2000, Volume: 93, Issue:3

    Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers

2000
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].
    Klinicheskaia laboratornaia diagnostika, 2000, Issue:7

    Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Apolipoproteins; Atenolol; Biomarkers; Complement

2000
In vivo and in vitro effects of isradipine on cytosolic Ca2+ concentration in erythrocytes from spontaneously hypertensive rats.
    American journal of hypertension, 1992, Volume: 5, Issue:12 Pt 1

    Topics: Animals; Calcium; Cytosol; Erythrocytes; Hypertension; Isradipine; Male; Rats; Rats, Inbred SHR; Rat

1992
Lack of effect of isradipine on cyclosporin pharmacokinetics.
    Fundamental & clinical pharmacology, 1992, Volume: 6, Issue:8-9

    Topics: Adult; Cyclosporins; Drug Interactions; Female; Humans; Hypertension; Isradipine; Kidney Transplanta

1992
A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 262, Issue:2

    Topics: Animals; Binding Sites; Blood Pressure; Brain; Calcium Channel Blockers; Calcium Channels; Dihydropy

1992
[Treatment of hypertensive crisis in outpatients with sublingual isradipine].
    Arquivos brasileiros de cardiologia, 1992, Volume: 58, Issue:3

    Topics: Administration, Sublingual; Adolescent; Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertens

1992
[Antihypertensive effect of isradipine: blood pressure determination with continuous ambulatory monitoring].
    Revista medica de Chile, 1992, Volume: 120, Issue:6

    Topics: Blood Pressure Determination; Blood Pressure Monitors; Female; Humans; Hypertension; Isradipine; Mal

1992
Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension.
    Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 3

    Topics: Aged; Blood Pressure; Blood Pressure Monitors; Calcium Channel Blockers; Dihydropyridines; Female; F

1992
Isradipine treatment for hypertension in general practice in Hong Kong.
    Chinese medical journal, 1992, Volume: 105, Issue:6

    Topics: Antihypertensive Agents; Dizziness; Family Practice; Headache; Hong Kong; Humans; Hypertension; Isra

1992
Combined actions of isradipine and captopril on renal function in hypertension.
    Journal of human hypertension, 1992, Volume: 6, Issue:5

    Topics: Adult; Captopril; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemodynamics;

1992
[Evaluation of the antihypertensive efficacy of isradipine SRO as assessed by ambulatory blood pressure determination].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1992, Dec-08, Volume: 81, Issue:50

    Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hypertension; Isradipine;

1992
[The calcium antagonist isradipine (Lomir) in the treatment of patients with essential hypertension].
    Terapevticheskii arkhiv, 1992, Volume: 64, Issue:9

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Drug Tole

1992
Isradipine improves platelet function in hypertensives.
    European journal of clinical pharmacology, 1992, Volume: 42, Issue:1

    Topics: Analysis of Variance; Antihypertensive Agents; Blood Platelets; Blood Pressure; Calcium Channel Bloc

1992
Influence of high sodium intake on urinary calcium excretion and cardiac calcium channels in spontaneously hypertensive rats.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1991, Volume: 9, Issue:6

    Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Creatinine; Dihydropyridines; Hyperten

1991
Timing of blood pressure measurements in determining anomalies in duration of effect of an antihypertensive drug: assessment of isradipine.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Isradipine; Mal

1990
Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients.
    Journal of cardiovascular pharmacology, 1990, Volume: 15 Suppl 1

    Topics: Aged; Aged, 80 and over; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Thera

1990
Comprehensive cardiovascular care with a first-line antihypertensive agent. Proceeding of a symposium. Basel, Switzerland, February 13-15, 1991.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Antihypertensive Agents; Dihydropyridines; Humans; Hypertension; Isradipine

1991
Reversal of left ventricular hypertrophy following treatment of hypertension with isradipine.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Dihydropyrid

1991
Serotonin and platelet activation during treatment with isradipine.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Aged; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hy

1991
Isradipine, a new calcium antagonist: effects on maternal and fetal hemodynamics.
    Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 3

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Fetus; Heart Rate; Heart

1991
Isradipine for treatment of acute hypertension after myocardial revascularization.
    Critical care medicine, 1991, Volume: 19, Issue:3

    Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Coronary Artery Bypass; Female; Hemodynamic

1991
Prevention of stroke and brain damage with calcium antagonists in animals.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain Damage, Chronic; Calcium Channel Blockers; C

1991
Negative inotropic activity of the calcium antagonists isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardium.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Antihypertensive Agents; Calcium Channel Blockers; Depression, Chemical; Diltiazem; Dose-Response Re

1991
Beyond lowering of blood pressure. . .isradipine. Satellite symposium of the thirteenth scientific meeting of the International Society of Hypertension.
    American journal of hypertension, 1991, Volume: 4, Issue:2 Pt 2

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridi

1991
Isradipine for hypertension.
    The Medical letter on drugs and therapeutics, 1991, May-31, Volume: 33, Issue:845

    Topics: Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridines

1991
Cardiovascular effects of isradipine in essential hypertension.
    The American journal of cardiology, 1991, Jul-01, Volume: 68, Issue:1

    Topics: Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Female; Hemodynamics; Humans; Hypert

1991
Reducing pulse pressure in hypertension may normalize small artery structure.
    Hypertension (Dallas, Tex. : 1979), 1991, Volume: 18, Issue:6

    Topics: Animals; Antihypertensive Agents; Arteries; Blood Pressure; Captopril; Dihydropyridines; Heart Rate;

1991
Isradipine, catecholamines, and pheochromocytoma.
    American journal of hypertension, 1991, Volume: 4, Issue:11

    Topics: Adrenal Gland Neoplasms; Adult; Blood Pressure; Calcium Channel Blockers; Catecholamines; Dihydropyr

1991
Effect of long-term isradipine treatment on the hypertension-dependent changes in coronary arteries in spontaneously hypertensive rats.
    Drugs under experimental and clinical research, 1991, Volume: 17, Issue:7

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Coronary Vessels; Dihydropyridines; Hypertension;

1991
Slow-release isradipine in mild to moderate hypertension: hemodynamic and antihypertensive effects.
    International journal of clinical pharmacology, therapy, and toxicology, 1991, Volume: 29, Issue:12

    Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination;

1991
Protective effects of antihypertensive treatment with isradipine on the consequences of cerebral ischaemia in the spontaneously hypertensive rat.
    Journal of hypertension, 1991, Volume: 9, Issue:2

    Topics: Animals; Antihypertensive Agents; Brain Ischemia; Hydralazine; Hypertension; Isradipine; Male; Motor

1991
Calcium antagonists in hypertension. Proceedings of a symposium. Bangkok, Thailand, February 9, 1990.
    Drugs, 1990, Volume: 40 Suppl 2

    Topics: Animals; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridines

1990
The calcium antagonist isradipine and its effect on blood pressure related to plasma renin activity.
    American journal of hypertension, 1990, Volume: 3, Issue:5 Pt 1

    Topics: Adult; Blood Pressure; Calcium Channel Blockers; Diastole; Female; Humans; Hypertension; Isradipine;

1990
Isradipine (Lomir) in the treatment of hypertension. Introduction.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridines

1990
Isradipine (Lomir) in the treatment of hypertension. An international satellite symposium of the Vth International Congress on Pulmonary Circulation. Prague, July 6, 1989. Proceedings.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridines

1990
24-hour ambulatory blood pressure monitoring in the treatment of mild hypertension with isradipine.
    Cor et vasa, 1990, Volume: 32, Issue:2 Suppl 1

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Electrocardiogr

1990
[Isradipine, a calcium antagonist in hypertension].
    Ugeskrift for laeger, 1990, Aug-20, Volume: 152, Issue:34

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridi

1990
[Isradipine in therapy of hypertensive pregnancy complications].
    Gynakologische Rundschau, 1990, Volume: 30 Suppl 1

    Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Infant, Newborn; Israd

1990
Repetitive natriuresis and blood pressure. Long-term calcium entry blockade with isradipine.
    Hypertension (Dallas, Tex. : 1979), 1987, Volume: 10, Issue:6

    Topics: Blood Pressure; Calcium Channel Blockers; Female; Glomerular Filtration Rate; Humans; Hypertension;

1987
Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure.
    Journal of hypertension, 1989, Volume: 7, Issue:2

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Hydralazine; Hypertension; Indoles; Isr

1989
Isradipine in hypertension. Proceedings of an international symposium. Athens, Greece, October 21, 1988.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Isradipine; Pyridi

1989
Treatment of hypertension with isradipine reduces infarct size following stroke in laboratory animals.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebral Infarction; Hypertension; Israd

1989
Long-term effects of isradipine on blood pressure and renal function.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Creatinine; Female; Glomerular Fi

1989
Detection and monitoring of asymptomatic atherosclerosis in clinical trials.
    The American journal of medicine, 1989, Apr-17, Volume: 86, Issue:4A

    Topics: Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Humans; Hydro

1989
Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1989, Volume: 7, Issue:6

    Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiomegaly; Drug Evaluation, Preclinic

1989
Characterization of dihydropyridine binding sites in the rat brain: hypertension and age-dependent modulation of [3H](+)-PN 200-110 binding.
    Brain research, 1987, May-26, Volume: 412, Issue:1

    Topics: Aging; Animals; Binding Sites; Brain; Calcium Channel Blockers; Dihydropyridines; Hypertension; Isra

1987
Antihypertensive and hormonal effects of PN 200-110, a new calcium-channel blocker, in essential hypertension.
    Journal of clinical hypertension, 1987, Volume: 3, Issue:4

    Topics: Adult; Aged; Angiotensin II; Blood Pressure; Calcium Channel Blockers; Dinoprostone; Female; Hormone

1987
Red blood cell ionized calcium concentration in spontaneous hypertension: modulation in vivo by the calcium antagonist PN 200.110.
    Clinical and experimental pharmacology & physiology, 1988, Volume: 15, Issue:4

    Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Erythrocytes; Hypertension; In Vitro Tec

1988